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Abstract 
The American Medical System’s AMS 800TM has been the gold standard for over 40 years 
with over 150,000 patients treated for Urinary Incontinence and is the leading treatment for male 
stress urinary incontinence (SUI) following prostate surgery. Type III SUI, or intrinsic sphincter 
deficiency, is the inability of the urethra to maintain closure pressure sufficient to keep the patient 
clinically dry at rest and during periods of heightened activity (~120 cmH2O; coughs, sneezes, 
posture changes, and exercises). The current AMS 800TM is not personalized to a patient’s needs 
and compromises with an in between pressure- as high (61-70 cmH2O) as it can be without 
exceeding safety threshold levels. As such many men still leak when they are active. The market is 
hungry for a device that can adapt to the patient’s level of activity, reducing pressure most of the 
day to protect the urethra and then briefly increasing the pressure when he is more active.  
 
We are developing a novel implantable pump (henceforth called “add-on device”) which 
will be an add-on to the AMS 800TM and it includes a solenoid coil-cum-plunger and a fluid 
reservoir within the pump body. The add-on device will be small, light-weight and battery powered, 
and maintain compatibility with the AMS 800TM device. The device idea is in its proof-of-concept 
stage. This add-on device can be a possible solution to reducing the risks including urethral atrophy 
(leading to return of incontinence) and erosion (leading to infection of the implant) resulting from 
the constant pressure.  
  iv 
Table of Contents 
 
List of Tables .................................................................................................................... vii 
List of Graphs .................................................................................................................. viii 
List of Figures .................................................................................................................... ix 
Introduction ......................................................................................................................... 1 
1.1. The Lower Urinary Tract System ......................................................................... 1 
1.1.1. The Urinary Bladder ..................................................................................... 1 
1.2. The Urethra .......................................................................................................... 3 
1.2.1. The Internal and External Sphincter ............................................................. 4 
1.2.2. The Prostate .................................................................................................. 6 
1.2.3. Micturition- The Urination Reflex and its Neural Pathways ........................ 8 
1.2.4. Urodynamic Terminologies- Pressure Profiles [15]–[17] ................................ 10 
1.2.5. Urodynamics and Continence ..................................................................... 11 
2. Prostate Cancer: Epidemiology and Treatment ........................................................ 14 
2.1. Global Incidence of Prostate Cancer .................................................................. 14 
2.2. Prostate Cancer in the United States .................................................................. 15 
2.3. Treatment for Prostate Cancer ............................................................................ 16 
3. Radical Prostatectomy and Incontinence .................................................................. 17 
4. Urinary Incontinence: Stress Urinary Incontinence .................................................. 20 
4.1. Stress Urinary Incontinence (SUI) ..................................................................... 21 
5. Stress Incontinence: Surgical Treatment .................................................................. 23 
5.1. Surgical Approach: Artificial Urinary Sphincter ............................................... 24 
6. Prior Design and Clinical Work: Timm, Scott, Bradley ........................................... 25 
7. AMS 800TM: Design, Components, Mechanism....................................................... 33 
7.1. Bulbar Urethral Placement: Perineal approach .................................................. 34 
7.2. Evolution of the AMS 800TM ............................................................................. 38 
7.3. Other AUS-like Devices ..................................................................................... 40 
7.3.1. FlowSecureTM (Sphinx Medical, UK) ......................................................... 40 
7.3.2. Zephyr ZSI 375TM (Mayor Group, France) ................................................. 40 
7.3.3. Silimed periurethral constrictor device (Silimed, Brazil) ........................... 41 
  v 
8. AMS 800TM Complications: Literature Survey ......................................................... 42 
8.1. Data Analysis ..................................................................................................... 44 
8.2. Surgical Methods for reducing Incidence of Complications .............................. 50 
9. Concept Generation: Lets Sketch.............................................................................. 53 
9.1. The Idea and the Motivation .............................................................................. 53 
9.2. Evolution of Pump Designs ................................................................................ 55 
9.2.1. Development of the Current Designs .......................................................... 62 
9.3. Designs Incorporated with Electromagnet ......................................................... 64 
9.3.1. Solenoids: Design and Fabrication ............................................................. 64 
9.3.2. Designs with the Adafruit Solenoid ............................................................ 67 
9.4. Characterization of the AMS 800TM Cuff: Pressure vs. Volume ....................... 72 
9.4.1. Pressure vs. Volume: Inside Cuff Only ...................................................... 72 
9.4.2. Pressure vs. Volume: Around Ovine Urethra ............................................. 73 
9.4.3. Clinical Study: Pressure-Volume Measurements on the AMS 800TM Cuff 74 
9.4.4. Conclusions from Ex-Vivo and Clinical Data ............................................ 77 
10. Other AUSs from the Literature ............................................................................ 79 
11. Actuation Circuit: Powering the Solenoid ............................................................. 84 
11.1. Some Basic Concepts ..................................................................................... 84 
11.2. Power Reduction Methodologies.................................................................... 86 
11.3. Mini 5V Push/Pull Solenoid: Further Characterization .................................. 90 
11.3.1. Solenoid Circuit 1 [64] (Appendix K)..................................................... 90 
11.3.2. Solenoid Circuit 2: Lowering Power Consumption (Appendix K) ......... 91 
11.3.3. Solenoid Force Experiments ................................................................... 92 
11.3.4. Energy: Possible Implantable Battery Technologies and Wireless 
Communication ......................................................................................................... 95 
12. Technical Specifications [71] ................................................................................ 97 
Current Status and Future Work ....................................................................................... 98 
References ......................................................................................................................... 99 
Appendix A: Findings about AMS 800 Complications from Literature Publications 
(1996-2016)..................................................................................................................... 105 
Appendix B: Comparison of Literature eAUS Prototypes [71] ...................................... 113 
Appendix C: Patent Survey (Courtesy Innography) ....................................................... 114 
Appendix D: Other Designs ............................................................................................ 118 
  vi 
Appendix E: Onshape Designs for 3-D Printing ............................................................. 119 
Appendix F: Delta Electronics Push Pull 5V Latching Solenoid (DigiKey) [63] .......... 119 
Appendix G: Mini 5V Push-Pull Solenoid from Adafruit Industries LLC [64] ............. 120 
Appendix H: Edward LifeSciences TruWave Pressure Transducer [93] ....................... 122 
Appendix I: TIP 102 (Complementary Silicon Power Darlington Transistors)- 
STMicroelectronics ......................................................................................................... 123 
Appendix J: iC-GE PWM Relay/ Solenoid Driver IC (1A) ........................................... 126 
Appendix K: OrCAD Circuit Schematics ....................................................................... 127 
Schematic 1: Adafruit recommended Circuit [64] ...................................................... 127 
Schematic 2: Power Reduction Circuit ....................................................................... 128 
Appendix L: Particle Photon Wi-Fi Module for Wireless Communication [78] ............ 129 
 
 
 
 
 
 
 
 
 
 
 
  vii 
List of Tables 
Table 1.1.  McNeal’s 4 prostatic anatomical zones (regarding urinary continence 
Zone 3 plays a vital role).………………………………………………………………..... 
 
6 
 Table 1.2. Urodynamic Terminologies used by Clinicians………………………… 
 
10 
Table 8.1. Comparative Study of Outcomes of AMS 800TM Implantations from 
1987-2017………………………………………………………………………….. 49 
Table 11.1. Solenoid Force measurements using a digital weighing scale when 
connected directly connected to the supply…………………………………………  
 
93 
Table 12.1. Comparative study of features of our prototype and other similar work 
 
97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  viii 
List of Graphs 
Graph 9.1. Pressure vs. Volume in Cuff only: Volume required to raise cuff 
pressure to 120 cmH2O in different cuff sizes. Polynomial Curve Fitting also 
shown. Volume determined using Wolfram Alpha………………………………..  
 
73 
Graph 9.2. Pressure vs. Volume in cuff when around Ovine urethra. Volume 
determined using Wolfram Alpha………………………………………………... 
 
73 
Graph 9.3. Pressure vs. Volume in 4 and 5 cm cuff in Patient 1………………… 
 
75 
Graph 9.4. Pressure vs. Volume in 4 cm cuff in Patient 2……………………….. 
 
75 
Graph 9.5. Pressure vs. Volume in a 4.5 cm cuff in Patient 3……………………. 
 
79 
Graph 9.6. Pressure vs. Volume Comparison in all 3 patients…………………… 
 
76 
Graph 9.7. Pressure vs. Volume in a 4cm cuff- ex-vivo, around ovine urethra 
and Patients 1 and 2………………………………………………………………. 
 
77 
Graph 11.1. Force vs. Voltage of the solenoid with Circuit 1…………………… 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ix 
List of Figures 
Figure 1.1. Median sagittal section of the male and female pelvis showing the 
Lower Urinary Tract………………………………………………………………... 
 
1 
 Figure 1.2. Frontal section of the female and male urinary bladder and urethra……  2 
Figure 1.3. Frontal schematic showing bladder base and entire length of the urethra 
 
 
3 
Figure 1.4. Anatomical sections of the male urethra………………………………. 3 
Figure 1.5. “Sphincteric urethra”………………………………………………….. 5 
Figure 1.6. Median section of bladder and urethra according to Henle……………. 5 
Figure. 1.7. Posterior view of the bladder and prostate…………………………….. 6 
Figure 1.8.  Sections of the Prostatic Central, Peripheral and Transition zones with 
respect to the urethra………………………………………………………………... 
 
 
7 
Figure 1.9. Integrated representation of the possible Urethral Sphincter (US) 
innervation pathways……………………………………………………………….. 
 
9 
Figure 1.10. Schematic representation of urethral closure pressure profile………… 10 
Figure 1.11. Diagram of continuous flow curve…………………………………… 10 
Figure 1.12. Diagram of intermittent flow  and corresponding pressures and curves 
of flow……………………………………………………………………………..... 11 
Figure 1.13. Factors affecting Urinary Continence………………………………… 13 
Figure 2.1. Prostate Cancer and mortality global, 2012……………………………. 15 
Figure 2.2. Prostate Cancer cases in the US, 2008-2016…………………………… 16 
Figure 3.1. Continence Rates and time to recovery in contemporary series of the 
past decade …………………………………………………………………………. 18 
Figure 3.2. Etiology of Postprostatectomy Incontinence…………………………… 19 
Figure 4.1. Classification of Urinary Incontinence……………………………….... 20 
Figure 4.2. Distinction between various form of symptomatology related to leakage 
of urine……………………………………………………………………………… 21 
Figure 4.3. Pressure loads acquired from a 28-year old continent subject during a  
1.8s cough event……………………………………………………………………. 22 
  x 
Figure 6.1.  Urethral clamps and stimulators to maintain urinary incontinence……. 25 
Figure 6.2. Diagrammatic views of deformable cuff……………………………….. 26 
Figure 6.3. (a) Stainless- steel bellows system; (b) Alternative hydraulic pressure 
system………………………………………………………………………………. 27 
Figure 6.4. Illustration of placement of cuff and experimental set up for determining 
cuff pressures required to prevent urine leakage from the bladder………………….. 27 
Figure 6.5. Total system for restoring the micturition reflex……………………….. 29 
Figure 6.6. Four parts of prosthetic urinary sphincter: reservoir, inflatable cuff, and 
two pumps…………………………………………………………………………... 29 
Figure 6.7. (A) Reservoir acts as fluid storage chamber between cuff fillings. (B) 
Hollow pump-bulbs are easy to compress and refill automatically when released. 
(C) Urethral occlusive cuff is formed by tying a flaccid rectangular pouch into an 
annular ring around the urethra……………………………………………………… 30 
Figure 6.8. Solenoidally controlled bellows for cuff pressure regulation………….. 31 
Figure 6.9. The delay-fill sphincter used only one bulb and the cuff repressurizes 
within 2 minutes after pumping of the pump bulb………………………………….. 31 
Figure 7.1. The AMS 800TM Urinary Control System……………………………… 33 
Figure 7.2. The major components of the AMS 800TM……………………………. 34 
Figure 7.3. Bulbous Urethral Cuff Placement- Perineal approach………………… 35 
Figure 7.4. Preparing the Cuff……………………………………………………… 35 
Figure 7.5. Preparing the Regulating Balloon……………………………………… 35 
Figure 7.6. Preparing the Pump……………………………………………………. 36 
Figure 7.7. The evolution of the AMS artificial urinary sphincter………………… 39 
Figure 7.8. AMS Artificial sphincter models used and their status as of 1986……. 39 
Figure 7.9. FlowSecureTM device………………………………………………….. 40 
Figure 7.10. Zephyr ZSI 375TM device…………………………………………….. 41 
  xi 
Figure 7.11. Silimed periurethral constrictor device……………………………….. 41 
Figure 7.12. Innovative characteristics of AUS compared with the current AMS 
800TM……………………………………………………………………………….. 
 
41 
Figure 8.1. Continence and Complication rates across publications for AMS 800TM 
and similar devices…………………………………………………………………. 
 
44 
Figure 8.2. Comparative outcomes of AUS implantations in contemporary cases 44 
Figure 8.3. Average Complication chart in 100 patients receiving an AMS 800TM 44 
Figure 8.4. Comparative Study of Outcomes of AMS 800TM Implantations from 
1987-2017…………………………………………………………………………... 
 
45 
Figure 8.5. Number of AUS cases in a year (2013 taken as example)…………….. 
 
47 
Figure 8.6. Push-pull measurement technique for urethral cuff sizing prior to cuff 
selection…………………………………………………………………………….. 
 
51 
Figure 8.7. Difference in dissection depth: Standard AUS vs Transcorporal 
Placement………………………………………………………………………….... 
 
52 
Figure 8.8. Continence and complications after AUS placement………………….. 52 
Figure 9.1. The Bellows pump as taken from Arvind Gupta’s Air-Water Pump….. 56 
Figure 9.2. The Diaphragm pump and its operating principle. Sketched on 
7/8/2015…………………………………………………………………………….. 
 
56 
Figure 9.3.  
 56 
Figure 9.4. Inserting a ring magnet into the shaft with opposite pole facing the 
second ring magnet to show "cordless bungee jumping"…………………………… 
 
57 
Figure 9.5. The Diaphragm-Piston pump actuated by permanent magnets and an 
electromagnetic coil. Sketched on 7/29/2015………………………………………. 
 
58 
Figure 9.6. Diaphragm Piston pump design 3D printed at the Medical Devices 
Center……………………………………………………………………………….. 
 
59 
Figure 9.7.  Keyboard switching mechanisms: The Scissor Switch and the Rubber 
Dome………………………………………………………………………………... 
 
60 
  xii 
Figure 9.8. The Rubber Dome pump. Sketched on 8/30/2016……………………… 
 
61 
Figure 9.9. O-Ring incorporated design with O-ring seals around the diaphragm 
and rolling diaphragm seals around the shafts within the diaphragm holes…………  
 
62 
Figure 9.10. (a) Pump with a life-saver shaped tube for fluid; (b) The usual rigid 
diaphragm idea as shown in Figure 8.9 (c); (c) Pump with AMS 800TM pressure 
regulating balloon; (d) A rectangular pump with AMS 800TM cuff………………. 
 
 
63 
Figure 9.11. Schematic drawing of the proposed electromagnetic transducer for a 
middle ear hearing aid……………………………………………………………… 
 
64 
Figure 9.12. Results of Force simulations for four different coil geometries……… 64 
Figure 9.13. A direct-acting solenoid valve with a ferromagnetic plunger………… 
 
66 
Figure 9.14. Pump using a solenoid actuating valve and AMS 800TM components.  
 
66 
Figure 9.15. Mini 5V Push-Pull Solenoid from Adafruit Industries LLC (Appendix 
G)…………………………………………………………………………………… 
 
67 
Figure 9.16. Mini 5V Push-Pull Solenoid with the pump design using the pressure 
regulating balloon to hold the fluid. (Sketched on 5/22/2017)……………………… 
 
68 
Figure 9.17. Onshape design and 3D printed model of a pump with rigid diaphragm 
to be used with the pressure regulating balloon……………………………………. 
 
69 
Figure 9.18. Pump design with in-built solenoid support with a pressure regulating 
balloon or nitrile glove……………………………………………………………...  
 
70 
Figure 9.19. Scaffolding for the Mini 5V Push-Pull Solenoid with the pump. 
(Sketched on 6/5/2017)…………………………………………………………….. 
 
70 
Figure 9.20. Pump designs with in-build solenoid scaffolding and nitrile 
diaphragms…………………………………………………………………………. 
 
71 
Figure 9.21. The lid design inspired from Figure 8.9 (d)………………………….. 
 
71 
Figure 9.22. AMS 800TM Occlusive Cuffs: 3.5cm, 4cm, 5 cm, 5.5 cm………….. 
 
72 
Figure 9.23. GobyTM portable urodynamics system setup………………………… 
 
72 
Figure 9.24. Sketch of the setup for the clinical study…………………………….. 
 
74 
  xiii 
Figure 9.25. The Edward LifeSciences TruWave Pressure Transducer as used in 
the University of Minnesota hospital OR………………………………………….. 
 
74 
Figure 9.26. Pressure vs. Volume measurements around an ovine urethra using the 
GobyTM portable urodynamics system setup………………………………………. 
 
78 
Figure 10.1. (a) Modified prosthesis GASS II; (b) Design with all mechanical and 
electrical components; (c) filling through the port………………………………… 
 
79 
Figure 10.2. Lamraoui et al’s Automated AUS (AAUS)…………………………… 
 
80 
Figure 10.3. Comparision of Ruthmann’s, Lamraoui’s and Hached’s work……….. 
 
81 
Figure 10.4. Hached et al.’s wireless AUS and it components……………………… 
 
81 
Figure 10.5. Hached’s prototypes with different sizes of casing. Size differences 
were attributed to pump sizes used …………………………………………………. 
 
82 
Figure 10.6. Proposed eAUS prototype and pressure control curves………………. 
 
82 
Figure 10.7. Concept design of the endourethral AUS……………………………... 
 
83 
Figure 11.1. Kartmann’s coil design……………………………………………….. 
 
86 
Figure 11.2. Comparison of the dimensions of Kartmann's prior functional model 
and the miniaturized design of the disposable, electromagnetic dispensing valve 
[65]…………………………………………………………………………………. 
 
87 
Figure 11.3. Comparison of PWM with and without current control [64]…………. 
 
89 
Figure 11.4. Current control with intelligent coil driver iC-GE.  [64]…………….. 
 
89 
Figure 11.5. Plunger Movement detection circuit………………………………….. 
 
90 
Figure 11.6. Solenoid Actuation Circuit 1 as recommended by Adafruit………….. 
 
90 
Figure 11.7. Solenoid Actuation Circuit 2 for Energy Saving…………………….. 
 
91 
Figure 11.8. Solenoid Force measurements setup…………………………………. 
 
92 
Figure 11.9. Solenoid Characteristics when connected to supply directly………….  
 
93 
Figure 11.10. Solenoid Characteristics when connected to Circuit 1………………. 
 
93 
Figure 11.11. Medtronic’s Micra Pacing System and the Sacral Interstim II 
Neurostimulator…………………………………………………………………….. 
 
95 
  xiv 
Figure 11.12. Wireless Communication with solenoid using Photon’s cloud-based 
interface on a cell-phone……………………………………………………………. 
 
96 
  1 
Introduction 
 
1.1. The Lower Urinary Tract System 
The lower urinary tract system (LUTS), (Figure 1.1) consists of the bladder and 
urethra in females and additionally, a prostate in males [1]. Sexual function and pelvic 
anatomy bring about significant variability in male and female LUT anatomy. While the 
kidneys are responsible for changing the composition and amount of urine, the LUTS is 
solely responsible for periodic elimination of urine [2].  
   
 
In infants, the bladder lies in the abdomen but with growth the pelvic bone develops 
and the bladder positions itself within the pelvis. The LUTS is susceptible to various 
disorders including overactive bladder, urinary incontinence (topic of this thesis), and 
prostatic and bladder carcinoma. This section will cover the anatomy, physiology, and 
histology of the bladder and the urethra.  
1.1.1. The Urinary Bladder 
The urinary bladder as shown in Figure 1.2, is a hollow muscular organ capable of 
storing urine and expelling it when socially acceptable. In males, it is superior to the prostate 
gland and in females, it is inferior to the uterus.  
Figure 1.2. Median sagittal section of the male and female pelvis showing the Lower Urinary Tract [1] 
  2 
The internal walls of the bladder are made 
up of several folds which allow the bladder 
to increase its capacity, for instance, at 
times when it is socially unacceptable to 
void one’s bladder. The transitional 
epithelium appears wrinkled when the 
bladder is empty and expands as urine fills 
up the bladder. As seen in Figure 1.2, the 
trigone is a triangular area inferior to the 
apex of the bladder which does not have the 
expandable transitional epithelium, also referred to as rugae, and is the site where the two 
ureters and the urethra have their openings [2].  
The musculature in the bladder that develops contractions within it are smooth 
detrusor muscles and as they accumulate around the urethral opening in the trigone, the 
muscles form the internal urinary sphincter which is an involuntary muscle. The urinary 
bladder has two principle functions [1]: 
• Reservoir for storage of urine- An adult bladder can store 500 ml of urine with excellent 
compliance which implies that it can store large volumes with minimal changes in 
pressure. Higher pressures at high volumes would lead incontinence or damage to the 
kidneys.  
• Generate sufficient pressure- Synchronized contractions of the detrusor muscle which 
initiates the voiding reflex called micturition (discussed in Section 1.1.3). 
 
 
Figure 1.2. (A) Frontal section of the female urinary 
bladder and urethra, (B) Frontal section of the male 
urinary bladder and urethra along with the prostate [2]
  3 
1.2. The Urethra 
The urethra (Figure 1.3) stems from the trigone and trigonal urethral opening, as 
discussed earlier is surrounded by the internal urinary sphincter (also called the sphincter 
of the bladder). This research deals with the male urethra and the next few sections will 
deal with some important parts of the urethra that are essential in explaining urinary 
incontinence, it treatment and the risks from the treatment options. 
 
 
Clinicians must keep in mind that the urethra changes direction suddenly at the end 
of the bulb of corpus spongiosum and care should be taken while inserting catheters for 
cystometric and other urodynamic studies. As we proceed further, we will extensively 
cover the risks of implanting an artificial urinary sphincter (AUS) to treat stress urinary 
incontinence. Prior to that, one must understand the vasculature (blood supply) to the 
urethra- the internal pudendal arteries predominantly supply blood to the urethra and 
urethral and penile blood drainage is through the internal pudendal vein [1].  
 
 
 
Prostatic Urethra
• 3-4 cm long passing antero-inferiorly through the 
prostate
Membranous Urethra
• Emerges from the prostate and pierces the urogenital 
diaphragm; 2cm long (Surrounded by the EUS*)
Bulbar Urethra
• Traverses the Bulb of corpus spongiosum; Changes 
direction by ~ 90 degrees from downwards to forwards
Penile (or Cavernous) Urethra
• Opens to the environment at the external urethral meatus; 
Enlarges at the Navicular fossa
Figure 1.3. Frontal schematic 
showing bladder base and entire 
length of the urethra [1] 
 
 
 
  
Figure 1.4. Anatomical sections of the male urethra including 
the smaller posterior urethra (prostatic and membranous 
urethra) and the longer anterior urethra (bulbar and penile 
urethra) [1] (*EUS: External Urethral Sphincter) 
 
  4 
1.2.1. The Internal and External Sphincter 
The internal sphincter at the bladder neck is formed by the smooth circular detrusor 
muscles and its physiology is better developed in males than females. The internal 
sphincter, also referred to as the “pre-prostatic” sphincter prevents retrograde emission of 
semen and contributes to urinary continence [1]. The external sphincter is secondary for 
continence [3]. 
The male external sphincter, also called the striated urethral sphincter is an integral 
component of the LUTS for preserving an individual’s ability to micturate. This complex 
musculature that forms the pelvic floor is innervated by the sacral nerve roots from the 
spinal cord [3]. In the previous section, where we discussed the different sections of the 
urethra, the naming of the membranous (Figure 1.4) urethra is considered a misnomer, and 
this has led to several problems in defining the anatomy and physiology of the external 
sphincter [3], [4].  The membranous urethra extends from the apex of the prostate to the 
corpus spongiosum. Several anatomical papers have discussed the importance of reaching 
a consensus surrounding the accurate nomenclature and recommendations have been made 
to change it to “sphincteric urethra” [3], [5]. Henceforth, the membranous urethra will be 
referred to as the sphincteric urethra.  
The striated urethral sphincter (s) as shown in Figure 1.5, is formed by the levator 
ani (la; Figure 1.5) musculature and in contact with the corpus spongiosum. Prominent 
contributions on the urethral sphincter came from researchers like Henle, Holl, and 
Kalischer in the 19th Century. 
  5 
Henle was the first in discovering that the 
urethral sphincter was composed of 
smooth and skeletal muscles, and he 
named this sphincter as the sphincter 
vesicae externus (Figure 1.6, {8}) to 
distinguish it from the smoother sphincter 
vesicae internus (Figure 1.6, {6}) [6]. 
The internal sphincter with its smooth 
muscles and elastic tissues is the primary 
sphincter [3], and in the presence of bladder 
neck dysfunction, the internal sphincter is 
essential for urinary control. An interesting 
find by Ficazzola and Nitti [7] was that 
incontinence after either transurethral or 
radical prostatectomy (RP) was attributed 
more to internal sphincteric deficiency than 
the external sphincter. In cases where the internal sphincter around the bladder neck failed, 
preservation of the external sphincter gained paramount importance. We will deal with 
prostatectomy in more detail in a later section.  
 
Figure 1.5. “Sphincteric urethra” might be more 
appropriate than “membranous urethra.” Coronal 
view through bladder @I), prostate (Pr), striated 
urethral sphincter (s), bulb, veins (V), obturator 
internus (oi), levator ani (la), anterior recess (AR) of 
ischioanal fossa, ischopubic ramus (R), and corpus 
cavernosum (c). (Sagittal inset for orientation.) [4] 
Figure 1.6. Median section of bladder and 
urethra according to Henle.1, bladder muscle 
wall. 2, ureteral orifice. 3, vas deferens. 4, 
seminal vesicle. 5, sphincter vesicae internus. 6, 
trigone longitudinal muscle layer. 7, prostate. 8, 
sphincter vesicae externus. [6] 
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1.2.2. The Prostate 
 
 
 
 
Like controversies surrounding the accurate nomenclature of the “membranous 
urethra”, several articles illustrate the controversies surrounding the anatomy of the 
prostate. However, for 25 years, John E. McNeal [8] presented his view of the prostate 
anatomy in terms of 4 anatomic zones [9].  
 
 
To understand the four anatomic zones of the prostate, McNeal divided the prostate with 
three reference planes [8], which are as follows (Figure 1.8. (iv)): 
• Sagittal plane: bisects the gland and reveals the urethral lumen in its full extent 
30% Fibromuscular and 70% Glandular 
Tissues
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Diameter: 4cm
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Figure. 1.7. Posterior view of the bladder and prostate, showing relationships between adherent 
structures and some physical characteristics of the prostate. [1] 
Table 1.1.  McNeal’s 4 prostatic anatomical zones (regarding urinary continence Zone 3 plays a 
vital role). [8], [9]  
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• Coronal plane: shows both the ejaculatory ducts and the distal urethra longitudinally 
• Oblique coronal plane: If the coronal plane is rotated by 35 degrees around the 
transverse axis that passes through the kinking in the urethra and follows the proximal 
urethra into the bladder. 
Figure. 1.8. (iv) highlights the 
importance of maintaining extreme care 
during transurethral or radical 
prostatectomy to allow the bladder to 
preserve urinary control. A review by S. 
Selman       [9] to understand the 
progression of McNeal’s anatomical 
zones brought forth some interesting 
points regarding the preprostatic 
sphincter in the preprostatic zone 
(described in Table.1). McNeal’s work published in 1972 [10], divided the prostatic urethra 
into two segments- the proximal and distal urethra (Figure 1.8. (ii);(iv)). The proximal 
urethra, also referred to as the preprostatic segment gave rise to the urethral glands and was 
surrounded by the cylindrical urethral sphincter, referred to as the “preprostatic sphincter” 
[9], [10]. This implies that sphincter, both internal and external includes the smooth 
sphincteric muscles around the bladder neck, the preprostatic sphincter in the proximal 
urethra, and the striated external sphincter muscles beginning at the caudal limits of the 
verumontanum.  
Figure 1.8.  (i) Sections of the Central and Peripheral 
zones taken perpendicular to the urethra. (ii) Sections of 
the prostate as seen from a sagittal plane. (iii) Transition 
zone of prostate introduced in 1978 as the site for 
development of Benign Prostatic Hyperplasia. [9].  
(iv) The sagittal (S), coronal (C), and oblique-coronal 
(OC) planes that highlight the ejaculatory ducts, the 
distal and the proximal urethra. [8] 
(i) 
(ii) 
(iv) 
(iii) 
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1.2.3. Micturition- The Urination Reflex and its Neural Pathways 
Having understood the anatomy and physiology of the sphincters and the prostate, 
understanding the voiding reflex or micturition will help us understand the different kinds 
of pressures applied on the bladder and the urethra.  
This spinal cord reflex allows exertion of voluntary control [2] and the stimulus is 
the stretching of the detrusor muscle. As the bladder fills up and the folds (rugae) of the 
inner lining begin to stretch, the sacral section of the spinal cord receives a sensory input, 
which activates motor impulses via the parasympathetic nervous system to induce detrusor 
contractions [2]. The internal urethral sphincter involuntarily relaxes, now subjecting the 
entire bladder pressure on the external sphincter over which we have voluntary control. 
Once we relax the external urethral sphincter, urine flows out of the urethra and empties 
the bladder [2].  
As discussed in Section 1.2.1, the internal sphincter is the primary sphincter and 
the external sphincter is the secondary sphincter. Voiding is situational and changes over 
time because of the state of the bladder [3], [11], [12], for instance situations like physical 
activity, auditory stimuli, fear and anxiety [3]. Yoshimura et al. found that micturition does 
not occur unless the urethral wall smooth muscles and the external sphincter contract. 
Micturition is controlled by the parasympathetic, sympathetic, and pundedal nerves 
(Figure. 1.9) [3], [11]. Studies have shown that the striated muscles of the external 
sphincter are 100% slow-twitch while the periurethral levator ani (Figure. 1.5) musculature 
is an amalgamation of slow and fast-twitch fibers [13]. This implies that the former 
passively assists in urethral closure once micturition is complete, while the latter is actively 
involved in maintaining musculature tone over prolonged periods to preserve continence, 
especially during events which cause an increase in intra-abdominal pressure [13]. From 
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my understanding, the levator ani musculature augments the urethral external sphincter’s 
functionality in maintaining continence.  
 
 
The reason for introducing the innervation pathways of the external sphincter is to build 
our pre-requisite knowledge on the etiology of incontinence stemming from neural injury 
post radical or transurethral prostatectomy, pelvic surgery, spinal cord injury, or traumatic 
brain injury. From my understanding, there is significant complexity involving cross-
communicating branches which brings in an element of neuroplasticity in the 
neuroanatomy of the external urethral sphincter [14].  
 
Figure 1.9. Integrated representation of the possible Urethral Sphincter (US) innervation 
pathways. 
Somatic pathway in dark blue; neurovascular bundle in green; pelvic plexus in red; 
communications in light blue.  
Co communicating branches, CN cavernous nerve, CS colliculus seminale, CT common trunk 
of the LAN and PuN, DNP dorsal nerve of the penis, EDs ejaculatory ducts, EUS external 
urethral sphincter, HN hypogastric nerve, LAF fascia of levator ani, LAM levator ani 
muscle, LAN levator ani nerve, NVB neurovascular bundle, P prostate, PF pelvic 
fascia, PPx pelvic plexus, PuN pudendal nerve, Re recurrent branches of the 
DNP, SoPPx somatic pelvic plexus, SN spongious nerves, LSN lesser sciatic notch, SV 
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1.2.4. Urodynamic Terminologies- Pressure Profiles [15]–[17]  
 
“Urethral closure pressure is the 
intraluminal pressure along the length of the 
bladder with the bladder at rest. Maximum 
urethral pressure is the maximum pressure of 
the measured profile (Figure 1.10). 
Maximum urethral closure pressure 
(MUCP) is the difference between the 
maximum urethral pressure and bladder 
pressure” [17]. 
 
 
Continuous flow (Figure 1.11) as described in [17] is in terms of flow time, which 
is “the time over which measurable flow occurs” and the time elapsed to reach maximum 
flow rate (highest point in the ‘bell’ curve; Figure 1.11) is called maximum flow time. The 
• The pressure within the bladder; [15], [16]
• The pressure recorded from a urodynamic 
catheter inside the bladder (Figure 1.12 
(ii))
Intravesical Pressure (Pves)
• Pressure surrounding the bladder; [15], 
[16]
• Estimated from rectal, vaginal, 
extraperitoneal, or bowel stoma
Abdominal Pressure (Pabd)
• Component of intravsical pressure created 
by forces in the bladder wall (passive and 
active) ; 
• Pdet =Pves - Pabd ; [15], [16]
Detrusor Pressure (Pdet)
• Measurement of the pressure/ volume 
relationship of the bladder during filling 
and voiding. [15]
Cystometry
• Volume at which a patient has a strong 
desire to void. [17]
Maximum Cystometric Capacity
• Maximum cycstometric capacity minus 
the residual urine.  [17]
Effective Cystometric Capacity
• Change in bladder volume and change in 
Pdet. [17]
Bladder Compliance
• Voluime of fluid expelled via urethra per 
unit time
Flow Rate
Table 1.2. Urodynamic Terminologies used by 
Clinicians  
Figure 1.10. Schematic representation 
of urethral closure pressure profile [17] 
 
Figure 1.11. Diagram of continuous flow 
curve [17] 
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area under the curve gives the voided volume and the average flow rate is the voided 
volume divided by flow time [17].  
Intermittent flow or continuous flow with substantial terminal dribbling (Figure 
1.12. (i)) brings into picture the difference between voiding time and flow time. Unlike 
continuous where the flow time and voiding time are equal, under a scenario with an 
intermittent flow, the flow time is different from voiding time [17]. As highlighted in 
Section 1.1.3, voiding is subject to changes in environment (temperatures falling), auditory 
stimuli, physical activity, or fear and anxiety. The implication is that when flow and 
pressure measurements are taking in a clinic, the readings will have certain inaccuracy 
stemming from the mentioned changes and activities. This creates a challenge when the 
readings are being used to diagnose a disease condition.  
 
 
1.2.5. Urodynamics and Continence  
Micturition when seen as a physical phenomenon can only occur when a gradient 
is established allowing urine to flow out. This means that urine flows from a point of high 
pressure to a point of low pressure. When the sphincters are observed as physical 
resistances or obstructions that resist urine flow out of the urethra, it means that the 
resistance must reduce to facilitate micturition. The smooth detrusor muscle is made of 
several contractile myofibrillar units [18] which begin the stretching of the bladder as it 
 
 
Figure 1.12. (i). Diagram of intermittent flow. (ii) Diagram of corresponding pressures 
and curves of flow. [17] 
(ii) 
(i) 
  12 
fills up with urine. As the bladder stretches and engages several myofibrillar units, the 
muscles are under tension and gather significant force that sends out nerve impulses to the 
sacral spinal segments to produce a muscle contraction. The tensions stored in the 
contractile units is one aspect, the other is the velocity at which this tension is released and 
the detrusor muscle units come back to their original position and in doing so push out fluid 
from the bladder. Contraction velocity [18] has an inverse relationship with the force stored 
in the muscles. Instances where the muscle fibers are elongated and in tension, upon 
release, the contraction velocity increases and so does the flow rate. As we near the end of 
complete voiding, the contraction velocity reduces thereby reducing the flow rate.  The 
detrusor muscles are mostly made of “slow-twitch” muscles (Section 1.2.3) but it’s 
anatomy is like striated and cardiac muscles and three times slower [18], [19].  
From an energy perspective, when the myofibrillar units are stretching as urine 
fills the bladder, sufficient potential energy is being built up and when the urethra opens, 
90% of the energy is converted to kinetic energy [18] and the rest is lost as heat because of 
friction against the urethral walls. There are two types of muscle contractions- isotonic and 
isometric contractions. Isotonic contractions are those where the tension remains the same 
and the muscle length changes, while isometric are those where the muscle length does not 
change. The contraction of the detrusor muscle is initially isometric and as the bladder 
empties, it becomes more isotonic [18]. 
Hald and Bradley [18] elaborated on some of the factors that affect urinary 
continence and some of them are listed in Figure  1.13. The bladder factor includes 
increased stiffness, detrusor over activity, and lack of detrusor contractility. The urinary 
bladder is a visco-elastic and this important physical characteristic affects the detrusor 
reflex. Researchers in the late 1960s demonstrated transmission on intra-abdominal 
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pressure on bladder and urethra and also showed that pressure rise in urethra is higher 
owing to the possible existence of the striated sphincter reflex contraction [18]. The striated 
urethral sphincter has been known to 
maintain passive continence in addition 
to active continence. Since the load on 
the closed sphincter is low, it requires 
less force to prevent incontinence.  
 
 
 
 
 
 
 
 
 
 
 
 
Urinary 
Continence
The Bladder 
Factor
The Bladder 
Neck Factor
The Pressure 
Transmission 
Factor
The 
Suspension 
Factor
The Levator 
Factor
The Striated 
Sphincter 
Factor
Figure 1.13. Factors affecting Urinary Continence [18] 
  14 
2. Prostate Cancer: Epidemiology and Treatment 
2.1. Global Incidence of Prostate Cancer 
Prostate cancer affected 1.4 million men in 2013 leading to 293,000 deaths 
and rendered 4.8 million men to live with some form of disability [20]. Incidence 
was higher in developed countries because of lifestyle and a higher aging population. 
Younger countries like those in Asia, experienced the lowest incidence of prostate 
cancer. In 2013, prostate cancer was the leading cause of death in men in 24 
countries. Prostate cancer is one of the most common cancers diagnosed in men. The 
number of incident cases increased four-fold in 2013 when compared with 1990 
because of an aging and growing population. Overall, incidence of prostate cancer 
is rising in most countries while in some the numbers have stabilized. Figure 2.1 
gives an insight into the incidence and mortality of prostate cancer in 2012. An 
interesting data point from the graph is that the mortality in less developed regions 
is higher than the more developed regions but the incidence rates are significantly 
higher in developed regions of the world. This ties into the availability of prostate 
cancer early detection programs in some countries.  
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Figure 3.1. Prostate Cancer and mortality global, 2012 (Source: International Agency for Research on 
Cancer, GLOBOCAN), [20] 
An estimated 307,000 men died in 2012 from prostate cancer making it the 5th leading cause 
of death in men. For the period of 2012-2020, trends in incidence rates suggest that the rise 
in prostate cancer in developing countries will be 1.6 times that in developed countries. The 
disease is expected to see 499,00 deaths by 2020 [20].  
2.2. Prostate Cancer in the United States 
“One in seven American men will have prostate cancer during his lifetime.[20]” 
The American Cancer Society estimates that currently there 2.8 million men living 
with prostate cancer and 10.7% of new cancer cases are prostate cancer cases. 
Prostate cancer occurs in older men and the risk of developing it increases 
exponentially between 40-69 years of age.  
  16 
2 million men living in the US live with 
prostate cancer and a whopping 17% 
will be diagnosed with this cancer. This 
cancer is rare before age 40 and two-
thirds of men diagnosed with prostate 
cancer are aged 65 years or older.  
2.3. Treatment for Prostate Cancer 
Radical prostatectomy with some variations is the treatment option for Stage 
I-III prostate cancer. External beam radiation therapy and interstitial implantation of 
radioisotopes are used in treating this cancer in its Stage I and II. Radical 
prostatectomy involves the removal of the prostate gland, some surrounding tissues 
and a few lymph nodes [20]. There are different ways to perform this surgery: 
• Robot-assisted surgery 
• Incision in abdomen 
• Incision between anus and scrotum 
• Laparoscopic Prostatectomy 
• Cryoablation 
There are two types of radical prostatectomy (RP): retropubic and perineal 
prostatectomy. The former involves the removal of prostate and nearby lymph nodes 
through an incision in the abdominal wall, while the latter involves removal of 
prostate through an incision made in the perineum.  
“Impotence and leakage of urine are some complications of surgery. [20]” 
Figure 2.2. Prostate Cancer cases in the US, 2008-
2016 [20].  
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3. Radical Prostatectomy and Incontinence 
Urinary incontinence is a major complication that affects several patients who 
undergo radical prostatectomy. Caregivers keep a track of micturition diaries, conduct 
pad tests, urodynamic studies and cystoscopy to understand the cause of incontinence 
in these patients. Post-prostatectomy urinary incontinence has been attributed to 
sphincter malfunction, detrusor abnormalities, and urinary retention with overflow 
[21]. Chao et al. [22] examined urodynamic record of 74 patients with urinary 
incontinence significantly affecting quality of life of patients post- radical 
prostatectomy. Of the 74 men, 42 had sphincter weakness alone, 29 had detrusor 
instability and/or decreased compliance combined with sphincter weakness and only 3 
had just detrusor instability. The reason for an increased susceptibility to detrusor 
instability and sphincteric malfunction has been attributed alterations in bladder and 
bladder outlet anatomy [23]. Most patients post-RP strain their abdomen to void their 
bladder because of detrusor underactivity and this directly affects treatment options for 
stress urinary incontinence which will be discussed in detail in later sections.  
Detrusor underactivity as defined by the International Continence Society is the 
“contraction of reduced strength and/or time resulting in prolonged bladder emptying 
and/or failure to achieve complete bladder emptying with a normal time span [23].” 
Maffezzini et al. collected data from 265 patients out of the 300 patients they were 
evaluating for post-RP complications and they found that at a median follow-up of 29 
months, 262 patients were continent and 26 had stress incontinence with varying 
intensities who had to wear one to three pads per day, and 7 patients were incontinent 
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and had to wear 4 or more pads. However, 80% to 93% regained urinary continence 
after a variable period of 3-24 months [24]. Maffezzini’s review of literature in Figure 
3.1, compared the study with others in the 1991-2000 period, and found that the 
recovery of continence was in a short time span and almost 48.2% of the incontinent 
patients achieved complete urinary control.  Different studies employed varied methods 
to collect the data but most had on an average 3-16 weeks to recover continence.  
 
      Figure 4.1. Continence Rates and time to recovery in contemporary series of the past decade [24] 
 Sphincteric malfunction is usually observed as constant, dribbling, 
gravitational, or stress-induced incontinence. On the other hand, patients who show 
signs of urge incontinence have detrusor abnormalities. Sometimes, both sphincteric 
malfunction and detrusor abnormalities can exist in a patient [21]. Several review 
studies trying to understand the causes of post-RP incontinence have listed the SAME 
in Figure 3.2. Some etiologies mentioned in the figure are mutually dependent and 
occur at the same time. Detrusor instability includes low bladder compliance, 
involuntary detrusor contractions, and impaired or absent detrusor contractility [21].  
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Sphincteric incontinence can be recovered from within 
months post-RP, but there are patients who have this 
complication intermittently and lasts for months. Apart 
from inconveniencing the patient it further affects the 
psychology of a patient who has just been out of a cancer 
surgical treatment. Some patients with incontinence that 
shows signs of improving use absorbent pads, but for 
severe incontinence patients use condom catheters or 
undergo surgery. Pharmacological solutions, electrical 
stimulation, and biofeedback are some possible solutions for treatment of incontinence 
but significant clinical evidence does not exist [21]. Physicians recommend surgery to 
treat incontinence usually after a year has elapsed from prostatectomy, but if the 
incontinence incidents are severe and do not seem to improve, surgery is recommended 
earlier. Physicians have to weigh the cost of surgery against the possibility that a 
patient’s conditions might improve suddenly and he will be continent henceforth. 
Sphincteric prostheses have been the mainstay of sphincteric incontinence and will 
continue to be and most physicians prefer using the sphincter prosthesis by American 
Medical Systems (AMS), Minnetonka, MN, USA.  
 
 
Figure 3.2. Etiology of 
Postprostatectomy Incontinence. 
[21], [23], [24]  
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4. Urinary Incontinence: Stress Urinary Incontinence  
As defined by the International Continence Society (ICS), urinary incontinence is “a 
condition where involuntary loss of urine is a social or hygienic problem and is 
objectively demonstrable [17]”. Urinary incontinence may or may not be termed as a 
problem based on what is acceptable in one society and to one person may be 
unacceptable in another environment and to other persons [17]. For this reason, the 
words “social and hygienic” bring in a factor of variability in the above definition.  
Urinary Incontinence was and still is defined by symptoms, signs, physical conditions, 
etiology, age, occurrence, and anatomical factors [18]. Therefore, there exists a need to 
classify urinary incontinence per different criteria. 
 
               Figure 5.1. Classification of Urinary Incontinence [18] 
This classification gives researchers the freedom to precisely describe large groups of 
patients with a similar clinical picture and identical urodynamic findings, although the 
etiology may be different [18]. 
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Symptoms and Signs 
With deeper understanding on urinary incontinence which could possibly be an episode 
with an extremely short time course, lasting a few seconds, or be prolonged, or 
continuous, researchers and clinicians need to develop an investigative protocol such 
that an incontinence episode is not missed [18]. Studies designed henceforth must 
consider both static hydrodynamic conditions in the lower urinary tract and situation of 
daily life, where the patient experiences incontinence. Emphasis has been given on the 
line of questioning where clinicians are curious about the time of first occurrence, and 
a previous history of urological, gynecological, nervous, rectal, and somatic diseases 
[18].  
 
       Figure 4.2. Distinction between various form of symptomatology related to leakage of urine [18] 
4.1. Stress Urinary Incontinence (SUI) 
Stress Urinary Incontinence (SUI) is the involuntary loss of urine during a 
physical movement like coughing, sneezing, exercising, laughing, or picking up heavy 
objects [25]. It occurs when the pelvic floor and urinary system’s structures are 
stretched, damaged, or defective [26]. When the bladder pressure exceeds the urethral 
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pressure during incidents like coughing, sneezing or other strain activities which 
increases intra-abdominal and hence, bladder pressure [27]. There is a lack of accurate 
measurement systems for obtaining dynamic pressure profiles which makes it harder 
to diagnose incontinence.  
Air-charged balloon on semi-rigid catheters are generally reliable and have 
reasonable response times to measure pressure during incidents of stress [27]. 
Maximum urethral closure pressures (MUCP; Section 1.2.4) are measured by 
subtracting the maximum bladder pressure from the maximum urethral pressure. These 
readings ate taken at rest and stress-inducing incidents like a cough. The maximum 
bladder pressure at rest and stress-induced incident is calculated usually 2cm inside the 
bladder. Continent subjects have a higher MUCP than incontinent patients when at rest 
but decreases significantly during cough/ strain maneuvers in incontinent patients [27].   
Spirka et al. (Figure 4.3) analyzed Pves and 
Pabd in a 28-year-old continent patient during 
a 1.8s cough and finite element analysis was 
used to model a bladder [28]. In 1978, Bunne 
et al. studied the urethral closure pressure in 
stress-incontinent and continent patients and 
concluded that stress incontinence occurs because of low urethral pressure and 
defective pressure transmission from abdomen to urethra [29].  
 
Figure 4.3. Pressure loads acquired from a 28-
year old continent subject during a 1.8s cough 
event [28] 
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5. Stress Incontinence: Surgical Treatment  
238,590 new cases of prostate cancer were estimated to arise in 2013 with an 
estimated 29,720 deaths with 1%-40% of patients suffering from urinary incontinence 
post-PR [30]. Literature suggests that 40% of patients with prostate cancer opt for 
radical prostatectomy. Post-PR, half of the patients seek treatment for incidences of 
incontinence, out of which 6%-9% elect surgery for treatment of incontinence [30].  
There are conservative and surgical techniques to treat incontinence. The 
former includes pelvic exercises and lifestyle modifications, while the latter usually 
includes the very successful procedure of implanting an artificial urinary sphincter 
(AUS). There are other surgical procedures as well like the male slings for mild 
sphincteric deficiency, but for our study, we will consider the AUS implantation 
technique. For most patients, urinary incontinence and its severity is measured by the 
number of absorbent pads used, a bladder diary, uroflowmetry, and cystoscopy. But 
these studies are performed in a clinical environment and are not the same as measuring 
and evaluating an incident in real time.  
Before the physician decides to proceed with the surgery, a thorough evaluation 
of the patient’s history, onset, duration, description of the type and severity of 
incontinence, weights of absorbent pads and number of leakage incidents is necessary. 
Understanding the effects of incontinence on a patient’s life is integral to treating this 
condition. Urodynamic studies confirm that 95% of patients with post-PR incontinence 
have stress urinary incontinence (SUI) [30].  
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5.1. Surgical Approach: Artificial Urinary Sphincter 
The AUS has been the gold standard for the treatment for SUI post-PR and 
the device has undergone several design iterations over the past several decades. The 
latest device is the American Medical System’s (AMS) AMS 800TM which consists 
of a fluid-filled cuff around the urethra and the pressure is maintained by a pressure 
regulating balloon with a control pump that allows the patient to activate/ deactivate 
the device.  
Understanding the implantation of the AUS was a major part of this thesis 
and with Dr. Sean Elliott’s help, we could gain insight into the procedure of 
implantation and activation of the AMS 800TM. The access to the bulbar urethra 
around which the cuff is wrapped is via a longitudinal midline perineal incision over 
the urethra. Several incisions through the bulbospongiosus muscle, the cuff is placed 
around the urethra, the control pump is placed in the scrotum, and the pressure 
regulating balloon is placed intra-abdominally or in an extraperitoneal prevesical 
space.   
Subsequent sections will deal with the AUS design, components, 
complications and our novel design and its evolutionary journey. The AUS has many 
complications which will be elaborated upon and backed by literature studies. 
Overall, patients are very satisfied with the success of the device and its ability to 
maintain continence and physicians recommend the AMS 800TM to all patients 
seeking a surgical approach, the journey of the device from an engineering 
standpoint has been historic and life-altering for several patients.  
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6. Prior Design and Clinical Work: Timm, Scott, Bradley 
Urological devices stemmed from the idea of involuntary dretrusor contractions that 
made patients incontinent. This could be the result of an injury or a disease condition 
due to damage to the autonomic and neural pathways that control the micturition reflex 
(the filling and evacuation of the bladder) [31]. Timm et al. worked on electronic means 
of simulating a normal micturition reflex including evacuation, retention and volume 
sensing [31]. Electronic simulation requires coupling to the neural pathways and a 
method using electrodes (positioned on the dorsal and ventral surfaces) was used to 
simulate micturition. Mechanical and electrical ways of maintaining continence were 
being worked upon simultaneously and this required awareness of neural pathways and 
which nerves sensed volume and stimulated the bladder to void [31], [32].  
In the same work, Timm et al., developed an inflatable cuff around the urethra which 
could provide continence. They 
were trying to demonstrate 
techniques for urinary 
incontinence using electrical and 
mechanical techniques. The set up 
and the components in their 
environment have been illustrated 
in Figure 6.1. Urethral clamps and 
stimulators were designed to maintain continence. In the hydraulic type as seen in 
 
 Figure 6.1.  Urethral clamps and stimulators to maintain 
urinary incontinence. (a) Clamp is opened and closed with an 
electromagnet. (b) Hydraulic mechanical clamp using inflatable 
balloon to open and close. (c) Electrical stimulation of external 
sphincter used to stimulate imparted pudendal nerve input. (d) 
Cuff placed around the urethra has inflatable inner balloon to 
    
(a) (b) 
(c) (d) 
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Figure 6.1, we can see the use of a reservoir attached to a cuff that maintained constant 
occlusive force on the urethra. The same concept is used in the AMS 800TM.  
In 1970, Timm et al. [33] designed a deformable cuff attached to a modified 
hydraulic system shown in Figure 6.1, which intermittently occluded a collapsible 
tubular structure like the urethra. The cuff, shown in Figure 6.2 inflates inwardly 
because of nylon sutures in its backing and this was the idea considered for the AMS’s 
current narrow-back cuff. An intravesical pressure equal to or greater than cuff pressure 
is required for urinary leakage and therefore the cuff should maintain higher pressures 
for maintaining continence. Figure 6.2 is a diagrammatic representation of the 
deformable cuff when unpressurized and pressurized.  
The work also highlights advances 
made in designing reservoirs and 
pumps that could maintain constant 
pressure in the cuff, and these are 
illustrated in Figure 6.3. The cuff was 
made of silicone rubber and one made 
of dacron-reinforced silicon rubber 
provided maximum pliability. The stainless-steel bellows system (Figure 6.3(a)) was 
considered the best in maintaining constant pressure at the time.  
Development in any medical device is inspired from prior short-comings and 
this has led to iterative design changes in urinary incontinence devices. In 1971, Timm 
described a device was comprised of an inflatable cuff (similar to the one in [33]) to 
Figure 6.2. Diagrammatic views of deformable cuff. (a) 
Inner balloon attached to reinforced backing. (b) Cuff in 
position but unpressurized. (c) Pressurized cuff occluding the 
encircled vessel. [33] 
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occlude the urethra and an internally implanted but externally controlled hydraulic 
system that can maintain pressure and periodically remove volume from the cuff [34]. 
 
 
 
The experimental arrangement for determining cuff pressure to prevent urine leakage 
is shown in Figure 6.4. The setup allowed continuous intravesical and cuff pressure 
measurements.  
 
Figure 6.3. (a) Stainless- steel bellows system for maintaining constant pressure in cuff. (b) 
Alternative hydraulic pressure system with cuff utilizing two-check valves and pliable chambers 
to permit activation of the cuff from outside. [33] 
(a) (b) 
Figure 6.4. Illustration of placement of cuff and experimental set up for determining 
cuff pressures required to prevent urine leakage from the bladder. [34] 
  28 
The device used the bellows system from [33] to maintain constant pressure on the cuff 
and each component was connected using silastic tubing. Clinical studies in dogs with 
this device showed that there was no tissue impairment from the cuff around the 
urethra. Cuff pressures lower than 80 cmH2O and 40 cmH2O in male and female dogs, 
respectively, did not show any signs of tissue impairment. However, going above these 
pressure values led to penis engorgement in males and tissue necrosis in females [34]. 
The study considered potential sources of complications that could limit the application 
of the device but were not observed in the animal studies. These included development 
of strictures, intolerable pain, tissue necrosis, and stress urinary incontinence at 
momentary high levels of bladder pressure [34].  
Control over lower urinary tract functions are lost during neurological diseases 
and spinal disorders, and Timm et al. developed implantable prosthetic devices for 
restoring bladder function using electrical dretrusor stimulation with occlusion and 
volume sensing capabilities [35]. Several biological problems needed to be solved 
before proceeding to an engineering design and these included- excitation-contraction 
coupling of smooth muscle cells, drestrusor contractile sequence, pain with stimulation, 
loss of muscle contractility, and candidate selection [35]. The system designed to 
restore the micturition reflex is shown in Figure 6.5 and it requires a combination of 
three techniques- urethral occlusion to maintain continence, volume sensing for 
determining appropriate evacuation time, and electronic stimulation to induce dretrusor 
contraction [35].  
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Simultaneously, in 1973, a 
mechanical device was implanted 
in patients for the treatment of 
urinary incontinence. Preliminary 
results using this device (Figure 
6.6) showed successful 
restoration of continence in all 
five patients. The prosthetic 
device consists of 4 parts: an inflatable cuff, two pumps, and a reservoir. The pumps 
are each used to deflate and inflate the cuff, respectively. This prosthetic sphincter was 
activated 44,000 times which is equivalent to activating the device 6 time/ day, 365 
days per years for full 20 years [36]. At this point, the surgical techniques still had to 
evolve [36], [37].  
 
Figure 6.5. Total system for restoring the micturition reflex. [35] 
Figure 6.6. Four parts of prosthetic urinary sphincter: reservoir, inflatable cuff, and two pumps. (A) 
Squeezing pump on right transports fluid from reservoir into cuff, and (B) squeezing pump on left deflates cuff into 
“open” position. (C) Implantation with bulbs placed in labia of female or in scrotum of male. [36] 
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We need to understand each component of this device that went on to be named 
the AS 721 as shown in a later section where we will discuss the evolution of the current 
device. The inflatable cuff was made from silicone rubber and come in varying sizes. 
The average size of the cuff is 2 cm wide and 8 cm long [38]. At this point, research 
into developing a universal cuff was ongoing. The reservoir was made from two sheets 
of thick silicone rubber formed into a sphere. The tear-drop shaped pumps were 
activated by palpitating them through the skin [38]. The components are shown in 
Figure 6.7.  
 
 
 
 
Figure 6.7. (A) Reservoir acts as fluid storage chamber between cuff fillings. (B) Hollow pump-
bulbs are easy to compress and refill automatically when released. (C) Urethral occlusive cuff is 
formed by tying a flaccid rectangular pouch into an annular ring around the urethra.  [38] 
(A) (B) 
(C) 
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Like the design as part of this thesis work (discussed later), Timm et al., 
developed an electromechanical bellows system (Figure 6.8) to deflate the cuff 
on patient command. These ideas were developed way back in 1976 and 
involved a certain amount of fluid to be injected to raise pressure to 70 cmH2O. 
This electromechanical device was coupled with radio frequency and removing 
this signal allowed the cuff to fill back up again, after voiding [38].  
 
In 1977, Burton et al. laid down the design criteria for an artificial urinary 
sphincter and there are listed as follows [39]: 
• Device should be totally implantable 
• Must be biocompatible 
• Pressure occluding urethra should be enough to prevent leakage but not 
impair urethral viability 
• Device should have automatic pressure-release 
• Device should allow intermittent removal of occlusion so that urine flow is 
not impeded 
• Operation of device should be easily understood by patient 
Figure 6.8. Solenoidally controlled bellows for cuff pressure 
regulation. [38] 
Figure 6.9. The delay-fill sphincter used only one bulb and the 
cuff repressurizes within 2 minutes after pumping of the pump 
bulb.  [39] 
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• Pressure regulating features should be inherent and not dependent upon the 
way the device is used 
• A failed device should leave a patient in his preimplant, incontinent 
condition 
• Must achieve long-term success for control of incontinence 
At this point, patient selection criteria were also established which are listed as 
follows [39]: 
• Complete emptying of bladder with less than 10 mL of residual volume 
• Adequate flow rate 
• No infection 
• Adequate intravesical volume 
• No uncontrolled hyperreflexia of dretrusor muscle 
• Adequate manual and mental dexterity to manipulate pump bulbs 
• No response to conservative measures 
• Incontinence for than 1 year in the case of pelvic trauma and selected cases 
of neurogenic bladder 
The AMS 800TM was inspired from the AS 742 (Figure 6.9) which was a delay-
fill sphincter that incorporated a balloon which applied constant pressure on the 
urethral cuff. The cuff is deflated by removing by the fluid and then takes 2 
minutes to fill back up again [39].  
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7. AMS 800TM: Design, Components, Mechanism 
The AMS 800TM  [Figure 7.1(a)] is used in cases of 
severe incontinence due to intrinsic sphincteric deficiency 
[40]. The device mimics the natural sphincter by performing 
the opening and closing of the urethra. The device has three 
components: the pressure regulating balloon, the control pump 
and the urethral cuff (Figure 7.2). As seen in Figure 7.1 (b), the 
cuff is filled with fluid and this is preventing urine from 
flowing out, which it would because of the loss in sphincteric 
activity. To void, the patient squeezes on the control pump in 
the scrotum, which draws out the fluid from the cuff and moves 
it to the pressure regulating balloon. The urine passes through 
the urethra and gradually the cuff fills back up automatically 
within 11 minutes.  
Sterile fluid free of particulate matter must be used to 
fill all the components because the presence of a foreign matter 
in a system with incompressible fluid can cause mechanical 
failure of the device and prosthetic dysfunction. The operating 
room manual recommends using normal saline water for filling 
the prosthesis. Usually, the perineal or trans-scrotal approach is used for bulbous 
urethra cuff placement and the patient is placed in a lithotomy position or supine 
position respectively. The cuff is sometimes also placed more proximal to the bladder 
 
 
 
 
Figure 7.1. (a) The AMS 
800TM Urinary Control 
System, (b) Closed cuff, (c) 
Pumping opens cuff, (d) Re-
pressurizes automatically 
[40].  
(a) 
(c) 
(b) 
(d) 
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at the bladder neck. Besides the components mentioned in Figure 7.2, the AMS 800TM 
Urinary Control System also includes an accessory kit with connectors, a quick-
assembly tool, and an optional inert package and deactivation package.   
 
Figure 7.2. The major components of the AMS 800TM [40] 
7.1.  Bulbar Urethral Placement: Perineal approach 
Just the surgical technique takes around 30 minutes and the patient 
preparation takes longer than the surgery itself. As part of understanding the 
working of the device, several procedures were observed and the technique 
usually followed is as follows (Figure 7.3): 
• A midline perineal incision is made and the bulbocavernosus muscle is 
dissected from the bulbous urethra. [Figure 7.3 (a)] 
Occlusive Cuff
Closes the urethra by 
applying pressure
Made of Silicone elastomer
Available in 13 sizes: 3.5cm 
to 11cm
Placed at Bulbous Urthra/ 
Bladder Neck
Pressure Regulating 
Balloon
Determines amount of 
pressure applied by the cuff
Implanted in the prevesical 
space
Available in 6 ranges: 41-50, 
51-60, 61-70, 71-80, 81-90, 
91-100 (cmH2O)
Pump
Implanted in the soft tissue 
of the scrotum
1.2cm wide and 3.3cm long
Upper (hard) part contains 
fluid resistors
Lower (soft) part is squeezed 
by patient at time of voiding
Deactivation Button: Stops 
fluid from being transferred 
between components 
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Source: Boston Scientific 
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• Place a cuff-sizer around the urethra such that it fits snugly around the urethra 
but doesn’t constrict the urethra. [Figure 7.3 (b)] 
• Select the appropriate cuff size that corresponds to the length seen from the 
previous step.  
• Prepare the cuff for implantation (Figure 7.4) such that the pillow cushion side 
faces the urethra and the mesh towards the outside.  
• Rotate the cuff, so the tube adapter on it is lateral to the urethral midline and 
position the tubing to avoid contact with the cuff.  
• Select the appropriate sized regulating balloon and make a suprapubic incision 
to reach the prevesical space and create a space for the balloon. [Figure 7.3 (c), 
(d); Figure 7.5] 
• Like the blunt dissection made to access the prevesical space for the regulating 
balloon, make another such for the scrotum and place the control pump in the 
scrotal pouch with the deactivation button facing the outward so that it is 
palpable. [Figure 7.3 (e); Figure 7.6] 
• Make all the connections with appropriate tubing and cycle the device to test 
the connections.  
•  The device system must be left in the deactivated mode for four-six weeks after 
implantation.  
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Figure 7.3. Bulbous Urethral Cuff 
Placement- Perineal approach [40] 
The AMS Suture-Tie 
connectors are used to 
connect the tubing. AMS 
Quick Connect Sutureless 
Window connectors are also 
available which should not 
be used in revision 
procedures involving 
previously implanted 
tubing. It takes a few minutes for the cuff to refill and close off the urethra.  
 
 
(a) Dissect Bulbovavernosus Muscle (b) Measure urethral circumference
(c) Locate prevesical space for 
Regulating Balloon
(d) Placement of the balloon through 
the abdominal incision made (e) Place pump in the pouch
Figure 7.4. Preparing the Cuff (a) Fill Cuff; (b) Roll end of cuff [40] 
Figure 7.5. Preparing the Regulating Balloon (a) Fill Balloon; (b) Rotate balloon [40] 
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7.2. Evolution of the AMS 800TM  
The artificial urinary sphincter came into existence in 1974 and it evolved 
over time to get to the current gold standard for treatment of post-PR- the AMS 
800TM or AS 800 [41]. AS 721, AS 761, AS 742, AS 791, AS 792 (Figure 7.7) were 
the previous designs that the current device had to go through before becoming the 
best option for alleviating urinary incontinence. The AS 721 consisted of a hydraulic 
cuff around the urethra, the fluid was contained in a reservoir placed behind the 
rectus muscle, two pumps for opening and closing the cuff each [41]. This led to the 
development of AS 761 because of pressure regulation difficulties. The pressure 
regulating balloon was introduced here but the device ran into roadblocks. The AS 
742 was the first and closest to the current device back in the days and involved the 
use of a pressure regulating balloon which filled the cuff passively in 3-5 minutes, 
thereby allowing the patient to void the bladder. AS 791 and AS 792 were 
refinements to this design and the former was designed for bulbous urethra while 
the latter was bladder neck.  The AS 800 included the refinements from AS 791 
Figure 7.5. Preparing the Pump (a) Place Tubing into filling solution; (b) Clamp 
tubing with ends in filling solution [40]. 
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AND 792 and reduced their disadvantages by introducing a deactivation button on 
the control pump and housing the valves, resistors and pump in one unit [41].  
The paper by Tage [41] discusses the 
success of these different AMS 
artificial sphincters and at the time that 
this paper was published (1986), there 
was only one AS 721/761 operational 
out of the 19 that were implanted in 
patients. The graph in Figure 7.8 gives 
us an idea about progression of the 
device and their overall success as implants in patients.   
 
       Figure 7.8. AMS Artificial sphincter models used and their status as of 1986 [41] 
 
0 10 20 30 40 50 60 70 80
AS 721 and AS 761
AS 742
AS 791 and AS 792
AS 800
AS 721 and AS 761 AS 742 AS 791 and AS 792 AS 800
Operational 1 7 45 26
Newer Model 10 13
Removed 2 8
Inactive 18 2 1
AMS Artificial Sphincters Implanted 
between 1974-1985 [32]
Figure 7.7. The evolution of the AMS artificial urinary 
sphincter [41]. 
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From this 1986 data, Hald found that the overall success rate of the AMS sphincters 
was 77%. He also concluded that patients with detrusor instability stemming from 
prostatectomy can be treated with such implants but those with detrusor hyperreflexia 
having a neurogenic etiology disqualifies patients as a candidate for artificial 
sphincters [41].  
7.3. Other AUS-like Devices 
7.3.1. FlowSecureTM (Sphinx Medical, UK) 
The device has four components as 
shown in Figure 7.9: a regulating 
balloon, a stress release balloon, a 
urethral cuff, and control pump. The 
device is implanted as a single unit 
which eliminates mechanical failures due to tubing and provides in-situ 
pressure management. We will discuss the complications of the AMS 800TM 
in later sections but it is important to highlight that the FlowSecureTM did 
not exceed 40 cmH2O, thus minimizing urethral erosion and atrophy [42]. 
Several publications have reported a high mechanical failure from pump 
perforation and infection as well [42], [43], [44].  
7.3.2. Zephyr ZSI 375TM (Mayor Group, France) 
Created in 2005 and commercially available in 2009, this single-unit 
silicone device comprises of two components (Figure 7.10): a cuff and a 
pump control unit [42], [44], [45]. The control pump is used to activate the 
Figure 7.9. FlowSecureTM device [43]. 
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device and also behaves as a pressure regulating tank which pumps normal 
saline water using a piston actuation mechanism. 
The ZSI 375TM has a reduced cost, lesser number 
of components, and opportunity to adjust cuff 
pressure and size [42]. This device has not been 
widely implanted and data seems to be 
disappointing.  
7.3.3. Silimed periurethral constrictor device (Silimed, Brazil) 
Created in the 1990s and popularized in 2000, 
this device (Figure 7.11) was intended for 
pediatric patients with deficient sphincter 
activity [42], [44], [46]. The cuff is linked to 
a self-sealing valve and pressure is applied on 
the cuff by injecting sterile saline. This device is inexpensive and patients 
do not have to operate a pump manually. The single unit design also makes 
the pump easier to use but constant cuff pressure can cause higher erosion 
and tissue ischemia. Mechanical failure attributed to frequent injection of 
saline is another drawback of this device.  
 
Figure 7.10. Zephyr ZSI 
375TM device [45]. 
Figure 7.11. Silimed periurethral 
constrictor device [46]. 
Figure 7.12. 
Innovative 
characteristics 
of AUS 
compared 
with the 
current AMS 
800TM [47].  
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8. AMS 800TM Complications: Literature Survey 
 
The previous section dealt with the evolution of the AMS artificial sphincters 
and each of their success rates. The AMS 800 has become a gold standard to treat 
urinary incontinence, especially stress urinary incontinence post-prostatectomy. The 
1986 publication authored by Tage Hald, talks about the complications observed in 
patients post-AUS implantation. Susceptibility to infections and possibility of urethral 
erosion were listed as major complications that usually led to termination of the 
sphincter treatment, sometimes permanently [41].  
Physicians in the 1974-1985 period removed the entire device in the case of an 
infection and implanted a new one. In cases where the infection had led to erosion of 
the urethra because of high pressure (scarring of the urethra, arterial hypotension) it 
was difficult to implant a new AUS [41]. Within these patients who had an erosion 
because of infection, some received a new AUS which failed permanently due to 
urethral erosion. These problems including urethral atrophy, tissue ischemia, and 
urethral erosion continue to affect the success rates of implants and in turn, the patient 
satisfaction levels. Urinary tract infection is also a very real problem. Researchers have 
also tried to find a suitable location to place the artificial sphincter and some consider 
the region behind the central perineal tendon as a good location [41].  
Per Crivellaro et al., SUI is a complication post-RP and different techniques of 
RP had different incidence rates. For instance, 4- 31% of patients undergoing robotic 
prostatectomy or 7-40% undergoing open RP have chances of contracting SUI [47]. 
This extensive review of SUI post-RP included every publication with the keywords 
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incontinence, radical, prostatectomy, and treatment. From this search, they found that 
AUS (Figure 8.1) had a high number of patients with sufficient follow-up data and 
continence rates ranging from 20-89% [47]. The overall complication rate for an AUS 
was 19.4% [47] and was the highest among other similar devices because of the high 
number of patients available. However, the AUS is the best option for severe 
incontinence. 
A similar review by James et al. [48] concluded through their analysis of several 
publications on the device that the AMS 800TM had very successful outcomes and 
patient satisfaction was very high. However, with significant follow-up data available, 
researchers could determine that the device was plagued by several complications 
including infection (0.5%-10.6%) and erosion (2.9-12%) [48]. Infection from any 
prosthetic device is a major complication and in the case of the AUS, it involves 
removal of the device [48]. The AUS is now surface treated with antibiotics to reduce 
infections.  
The method used for analyzing publications on the complications of the AMS 
800TM is based on the idea that every device has a certain gestation period before it is 
accepted and made popular by physicians. We analyzed all the literature beginning 
from 1990 to 2016 (Appendix A) and the device was used in patients in mid-1983. This 
gives us a gestation period of about 5 years which is acceptable for any device since it 
will undergo design changes and iterations based on physician feedback and patient 
satisfaction.  
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                 Figure 8.1. Continence and Complication rates across publications for AMS 800TM and similar devices [47].  
 
            Figure 8.2. Comparative outcomes of AUS implantations in contemporary cases [48] 
8.1. Data Analysis 
The results from the data 
analysis of several publications 
on the AMS 800TM implant is 
used to understand the market 
for urinary incontinence post-
RP.  The data from 1987-2017  
 
Figure 8.3. Average Complication chart in 100 patients receiving 
an AMS 800TM implant (derived from Figure 7.4) 
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Figure 8.4. Comparative Study of Outcomes of AMS 800TM Implantations from 1987-2017 (Numbers have been rounded to nearest whole numbers) (Refer Table 8.1) 
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was tabulated in percentages and then brought down to whole numbers based on the 
total number of patients. Complications including erosion, atrophy, surgical 
revision, explantation, and mechanical failure were tabulated against each reference 
and then plotted onto a stacked bar chart shown in Figure 8.4. As shown in Table 
8.1, the total number of complications in each category across all publications was 
determined. Calculation of the mean of all complications against an average number 
of patients in all the publications helped determine the average percentage of patients 
suffering from each complication and designed the pie chart as shown in Figure 8.3. 
74% of all patients with an implanted AUS experienced some form of complication 
and had to go back for a revision or a follow-up. This data does not reflect the follow-
up time in each study since several references in Appendix A highlight the 5-year 
and 10-year durability outcomes of the device. The numbers used in the data analysis 
here is more of a cumulative value including patients who undergo secondary or 
tertiary revisions, or patients who are implanted with a tandem-cuff, or patients with 
multiple incidences of erosion, atrophy, mechanical failure or infections.  
Consider Singla et al. [30] and the statistics this publication provided with 
respect to the number of patients suffering from SUI and those undergoing surgery. 
The assumptions we make are: 
• Number of new cases in a year (2013) is considered instead of total number of 
patients with prostate cancer over a certain number of years.  
• Build a yearly market assessment for SUI and those undergoing surgery 
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• For patients undergoing surgery, we assume they are all implanted with the AMS 
800TM only.  
• Cumulative number of patients undergoing  
Based on data from [30], we 
have on average 1,476 cases of 
AMS 800TM implantations. 
Brown et al. [49] in 1998 found 
that the average Medicare and 
non-Medicare cost for an AUS 
implant was $15,400 and 
$20,300, respectively. If one 
accounts for inflation between 
1998 and 2013 (compare with 
Figure 8.5), the average 
Medicare cost would be $30,000 in 2013. The average reoperation rate was 22.4% 
which brought the average Medicare cost to $18,850 [49] and accounting for inflation 
this would be $32,000 in 2013. This gives us a $44.3 million market in 2013 alone and 
this considers only the new prostate cancer cases that came up in 2013.  
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑀𝑀𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇𝑇𝑇= 𝐴𝐴𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇 𝐶𝐶𝑇𝑇𝐶𝐶𝑇𝑇 ×  𝑃𝑃𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇𝑃𝑃𝑇𝑇𝐶𝐶 𝐶𝐶𝑇𝑇𝑇𝑇𝑀𝑀𝑀𝑀𝑃𝑃𝑇𝑇 𝐶𝐶𝑠𝑠𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑠𝑠 𝑓𝑓𝑇𝑇𝑇𝑇 𝑈𝑈𝑈𝑈 = $30,000 × 1467 𝑝𝑝𝑇𝑇𝑇𝑇𝑝𝑝𝑇𝑇𝑇𝑇 = $44,010,000 = $ 44 𝑚𝑚𝑀𝑀𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇𝑃𝑃 
Figure 8.5. Number of AUS cases in a year (2013 taken as example) [30] 
New Cases of 
Prostate Cancer 
(2013)  
238,590
Patients Opting 
for Radical 
Prostatectomy 
95,436
Patients with UI 
post-RP      
954-38,174
Patients seeking 
Surgery for UI 
Average: 
1,467
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With 1,467 patients undergoing surgical intervention to treat SUI post-RP, 74% 
(Figure 8.3) of these come back with some complications. However, from publications 
underscore the effectiveness of this device and estimate continence rates at 20% to 89% 
[47]. Though this number seems to be very high when compared to the overall 
complication rate of 19.4% published in [47], it gives innovators like us the motivation 
to make an even better attempt at reducing these complications and improving the 
quality of life. The reason for a high complication rate, as mentioned earlier, is because 
we have assumed every case as a new case and have not considered a mean follow-up 
time as in many studies. This helps us determine the higher side of the market. If all 
the 74% of the patients came back for a surgical revision, the revision rate would be 
very high, which reiterates our assumption of not considering the follow-up time. Most 
patients at some point with the AMS 800TM will come back to his physician with a 
complication irrespective of the number of days they have had the device. Some, which 
as shown in Figure 8.3 is 26%, will have an improvement in their continence, will be 
satisfied with using 0-1 pads per day, and will be complication free.  
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Table 8.1. Comparative Study of Outcomes of AMS 800TM Implantations from 1987-2017 (Numbers have been rounded to nearest whole numbers) (Refer Figure 8.4) 
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8.2. Surgical Methods for reducing Incidence of Complications 
From the extensive literature survey, the fact that the AUS has been a very 
successful device and the surgical procedure followed provides excellent patient 
satisfaction. Certain complications make patients undergo revisions or 
reimplantations and the most common reason for revisions was urethral atrophy. 
Such complications reintroduce incontinence in a patient and a pelvic X-ray and 
cycling of the device can show that the diameter of the pressure regulating balloon 
has reduced and there is excess fluid in the cuff [48].  
In cases of atrophy, physicians usually opt for cuff-downsizing and place the 
new cuff in the same location as before. American Medical Systems makes cuffs 
with the lowest being 3.5 cm. In cases where the smallest cuff has already been used 
or is not tight enough, physicians perform a tandem-cuff procedure or a 
transcorporal cuff-placement.  In a review by Hudak and Morey [50], 67 patients 
with the 3.5 cm cuff were studied to understand the effectiveness of the cuff-size 
compared to others and its impact during primary and revision surgeries. 45 patients 
underwent primary and revision AUS surgery without any difference in the 
methodology, and 8 patients underwent transcorporal cuff placement. The study 
found the patients with the 3.5 cm cuff had a higher chance of erectile dysfunction 
and urethral erosion compared to those with a 4.0 cm cuff [50].  
Papers on comparative outcomes of different treatments for prostate cancer 
consider prostatectomy as a contributor to urethral atrophy, decreased penile length 
due to collagenation, and decreased vascular supply leading to ischemia. Radiation 
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therapy has also been considered to cause small vessel obliterative endarteritis, 
increasing the risk of atrophy further.  There has been a shift in the way the cuff is 
measured and physicians pay special attention to the way they use the measuring 
tape provided in the device package (Figure 8.6). Hudak and Morey observed that 
a loose AUS cuff can cause significant 
incontinence requiring revision surgery.  
Tandem cuff placement was developed in 1997 in 
patients who suffered from UI despite a single-cuff 
placement and was usually attributed to 
insufficient urethral coaptation. A second cuff was 
placed a few centimeters away the existing cuff 
using a Y-connector. Studies found that the erosion rates for tandem-cuffs and 
single-cuffs were comparable, even though one would think that the tandem-cuffs 
would increase erosion. The success rate of tandem-cuff placement procedures was 
95% [48]. Urethral atrophy occurs when blood supply is limited to the urethra and 
periurethral-tissues [51]. A lack of urethral compression or coaptation is observed 
in cystoscopy even though an activated AUS is present around the urethra and 
requires a tandem cuff placement, a reduced cuff-size, higher pressure regulating 
balloon, or a transcorporal cuff.  
  A transcorporal approach in AUS revision cases uses incisions in the tunica 
albuginea of the corpora cavernosum which avoids a perineal incision in the corpus 
spongiosum [48]. Guralnick et al. [52] studied the effects of a transcorporal cuff 
Figure 8.6. Push-pull measurement 
technique for urethral cuff sizing prior to 
cuff selection. [50] 
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placement in patients with limited urethral coaptation and increased incontinence 
despite the presence of an AUS and 84% of the patients in the study responded 
positively to the procedure. The study did not find any case of erosion or infection 
but the patients do run the risk of developing erectile dysfunction. Figure 8.7 shows 
a comparison between a standard AUS placement dissection usually performed in a 
primary surgery and the transcorporal placement performed in a revision surgery 
[52]. In another study by Aaronson et al. [53], 18 patients underwent standard AUS 
surgery and 8 underwent transcorporal 
procedures, and it the data from their study 
was very interesting and is presented in 
Figure 8.8.  
  
 
The tandem cuff procedure is less 
popular when compared with the 
transcorporal approach and with the 
introduction of the 3.5 cm cuff, it has become less popular [48]. When cuff-
downsizing alone is taken as a measure to mitigate AUS complications, Saffarian et 
al. [54] found that in 17 patients with in whom the larger cuffs were replaced by a 
4cm cuff, patient satisfaction was 80% after cuff-downsizing. Cuff-downsizing also 
plays into the perfect urethral location for cuff placement and there are several 
papers on cuff locations which is beyond the scope of this thesis. 
Figure 8.7. Difference in dissection depth. (A) for 
standard artificial urinary sphincter cuff placement 
dissection plane (arrows and curved line) (B) for 
transcorporal cuff placement [52] 
Figure 8.8. Continence and complications after AUS 
placement [53]. 
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9. Concept Generation: Lets Sketch  
9.1. The Idea and the Motivation  
The device would be an accessory to the AMS 800TM for treating stress 
urinary incontinence (henceforth our device is called the add-on device). The idea 
originated from a simple problem that was observed in patients with the existing 
AUS, where patients had leakage during exercise, coughing and sneezing. When 
viewed as a technical problem, it was found that the current device applied a pressure 
that was much lower than the pressure applied on the bladder when a person 
exercises, coughs or, sneezes. In addition to the excess pressure, the several 
complications that plague the existing device were motivating factors to come up 
with a device. The major advantage of this device modification would be that it 
permits the occlusion pressure to be set at a much lower average value, thereby 
improving tissue perfusion, reducing ischemia and preventing urethral atrophy and 
erosion. The innovation would develop a way in which a nominal pressure can be 
applied through the cuff onto the urethra at rest but the pressure can increase rapidly 
in response to the patient activating a switch when he gets a feeling of possible stress 
on the bladder (e.g., during exercise, coughing or sneezing).  
The research team appreciates the simplicity of the current device and it is 
safe to say that the device has worked for so long because of its simple mechanism 
and biocompatibility. In our study and brainstorming sessions, we found that having 
the existing Pressure Regulating Balloon (PRB), control pump and the AMS 800 
cuff as part of the design will help reduce research time and in the long run- time 
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to market. Our concept would implant the 41-50 cmH2O pressure regulating balloon 
(the lowest pressure balloon that AMS has) because this would help maintain a 
constant fixed pressure on the cuff when the patient is sedentary/ inactive. The novel 
implantable pump in turn would bring pressure up to 120 cmH2O when incidents of 
stress occur. 
The questions that we needed to ask ourselves were: 
• Within what time-frame would the pump have to actuate? 
• Since coughs and sneezes are difficult to detect, how would we anticipate such 
incidents? 
• What kind of actuation mechanism will be the best for a quick response?  
• Can a patient control it wirelessly?  
• As an implantable, what kind of battery storage are we looking at? 
• Why retain the AMS 800TM components? Can we get rid of them completely?  
• What is maximum pressure during a stress-inducing incident?  
• How much volume would be required to raise pressure from an optimal value to 
the maximum pressure during a stress-inducing incident?  
As we dive deeper into answering some of these questions and find solutions 
to a problem that has existed for very long, as engineers it is essential to interact 
with the medical community and find out if there is a need for a device like this and 
if they would be willing to accept changes to the existing device. From a medical 
standpoint, we found out that this was an urgent need and could significantly 
improve quality of life for patients suffering from incontinence.  
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Our discussions with Dr. Sean Elliott in the Department of Urology at the 
University of Minnesota helped shape, solidify and pivot our idea time and again. 
When asked about the importance of an adaptive AUS, he had the following to say 
and that was our cue to begin working. Working with the creator of the device- Dr. 
Gerald Timm, there was constant feedback on ways we could tweak our prototype 
and present it as a viable option to treat the condition.   
The current AMS 800TM is not personalized to the patient’s needs. Most 
men only need 20 cmH2O of urethral compression to remain dry when 
they are sedentary, yet need 120 cmH2O when active. The current 
device compromises with an in between pressure- as high as it can be 
without exceeding a safe threshold. The market is hungry for a device 
that can adapt to a patient’s level of activity.   
Sean Elliott, MD, MS 
9.2. Evolution of Pump Designs  
We kept two things in mind: quick response time and implantability of the 
device. In our search for ideas to have a quick-action pump, we looked at several 
toys that had a water pump in-build into them. Most were comparable to simple 
piston pumps that needed considerable manual effort to actuate. I have always been 
fascinated by toys made from trash and we decided to search for pump ideas from 
do-it-yourself (DIY) manuals. I got my pump design ideas from three designs from 
Arvind Gupta’s “Toys from Trash” webpage [55] and a combination of these pumps 
into a single unit would be perfect for our application. For every pump design, we 
had to weigh them against the actuation mechanism and many had to be filtered out 
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for requiring significant effort to actuate. This would go totally against our 
requirement for a quick-action pump. Arvind Gupta’s Air-Water Pump design [55], 
[56] caught my eye. The design as I drew it in my journal is shown in Figure 9.1. 
and I called this a Bellow pump.  
Arvind Gupta in collaboration with Suresh 
Vaidyarajan published a DIY book titled  
“Pumps from the Dump” [56] and this was a 
treasure trove of various kinds of materials one 
could use to make a variety of pumps. A design 
titled the Diaphragm Pump [56], seemed a viable 
idea. It used a jam lid and balloon to pump water 
from a reservoir by manually pushing on the 
balloon diaphragm. I decided to try this out on a Coca-Cola bottle cap and the size 
of the cap was just enough to be an implantable. I used the specifications of a Coca-
Cola bottle cap to design my diaphragm pump using the same idea as in the book 
with a few minor tweaks. Figure 9.2 illustrates the design, components and operating 
principle and Figure 9.3 depicts this design with a rubber balloon diaphragm.  
  
 
 
 
 
 
 
Figure 9.1. The Bellows pump as taken 
from Arvind Gupta’s Air-Water Pump [46], 
[47]. Sketched on 7/8/2015.  
 
Figure 9.2. The Diaphragm pump and its operating 
principle as taken from [47]. Sketched on 7/8/2015.  
  
Figure 9.3. Design in Figure 9.2 realized 
using a balloon diaphragm and MinuteMaid® 
bottle cap.  
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The design of the diaphragm pump was a platform for more work. Actuating 
the designs was a major part of designing an implantable pump and we looked at 
several existing micropumps and motors that could work effectively for our 
application. Th disadvantage of purchasing a micropump or micromotor was the cost 
of such a device. But the idea of an electromechanical actuation was very interesting 
and we considered actuating the diaphragm using permanent magnets. The idea 
came from a setup that produced a damped motion of two magnets along a shaft 
with the opposite poles facing each other. This idea on a large scale was used to 
create a cordless bungee-jumping setup where the participant wore a magnetic suit 
that was oppositely polarized to the magnets on the ground and the magnetic 
repulsive force allowed cordless damped vertical motion of the participant. 
Illustrations depicting the setup with some initial sketches of this “cordless bungee-
jumping” idea incorporated in our implantable pump are shown in Figure 9.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) (c) 
Figure 9.4. (a) Inserting a ring magnet into the shaft with opposite pole facing the second ring 
magnet; (b) Vertical motion because of magnetic repulsive forces; (c) Time dependent damping of 
the magnet’s motion; (d) Sketch of the diaphragm pump in Figure 8.3 with a magnet and a solenoid.  
Ring 
Permanent 
Magnets 
(d) 
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The motion of two oppositely polarized magnets gave birth to idea of using 
solenoids. But, we wanted to completely rule out the idea of using two magnets as 
shown in the setup in Figure 8.4 to actuate the diaphragm. The advantage of just 
using permanent magnets is power conservation but the disadvantage is the constant 
motion of the magnet before it settles will cause occlusive cuff pressure fluctuation 
when used in the actual device.  One of the designs made using this magnetic 
actuation mechanism was a combination of a piston-diaphragm pump as shown in 
Figure 9.5.  
The working principle for this magnetic 
piston diaphragm pump was the simple 
application of the law that like poles of a 
magnet repel each other and unlike poles 
attract. It also uses the rule that the 
change in direction of current through a 
coil alters the magnetic poles on an 
electromagnetic coil. This pump design 
needed two magnets, one electromagnet 
and a rigid diaphragm that moved 
vertically along a shaft. With 3D-printing gaining traction and its advantages in rapid 
prototyping, I printed a few designs using the Medical Devices Center’s 3D printing 
facility. One of the designs I printed along with its dimensions is shown in Figure 
9.6 and the volume calculations for this pump are also shown.   
Figure 9.5. The Diaphragm-Piston pump actuated by 
permanent magnets and an electromagnetic coil. 
Sketched on 7/29/2015.  
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𝑉𝑉𝑇𝑇𝑇𝑇𝑠𝑠𝑚𝑚𝑇𝑇 𝑇𝑇𝑓𝑓 𝑇𝑇𝑀𝑀𝑙𝑙𝑠𝑠𝑀𝑀𝑀𝑀 𝑤𝑤𝑀𝑀𝑇𝑇ℎ𝑀𝑀𝑃𝑃 𝑇𝑇ℎ𝑇𝑇 𝑝𝑝𝑠𝑠𝑚𝑚𝑝𝑝 𝑏𝑏𝑇𝑇𝑀𝑀𝑠𝑠= 𝑉𝑉𝑇𝑇𝑇𝑇𝑠𝑠𝑚𝑚𝑇𝑇 𝑇𝑇𝑓𝑓 𝑈𝑈𝑃𝑃𝑃𝑃𝑇𝑇𝑇𝑇 𝑀𝑀𝑠𝑠𝑇𝑇𝑀𝑀𝑃𝑃𝑀𝑀𝑇𝑇𝑇𝑇 − 𝑉𝑉𝑇𝑇𝑇𝑇𝑠𝑠𝑚𝑚𝑇𝑇 𝑇𝑇𝑓𝑓 𝐶𝐶𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇 𝑆𝑆ℎ𝑇𝑇𝑓𝑓𝑇𝑇 
 =  𝜋𝜋𝑇𝑇12ℎ −  𝜋𝜋𝑇𝑇22ℎ = 5.91𝑀𝑀𝑀𝑀 − 0.77𝑀𝑀𝑀𝑀 = 5.14𝑀𝑀𝑀𝑀 
𝑇𝑇1 = 𝑈𝑈𝑃𝑃𝑃𝑃𝑇𝑇𝑇𝑇 𝑇𝑇𝑇𝑇𝑀𝑀𝑀𝑀𝑠𝑠𝐶𝐶 𝑇𝑇𝑓𝑓 𝑝𝑝𝑠𝑠𝑚𝑚𝑝𝑝 𝑏𝑏𝑇𝑇𝑀𝑀𝑠𝑠 = 13.855 𝑚𝑚𝑚𝑚;  
𝑇𝑇2 = 𝑅𝑅𝑇𝑇𝑀𝑀𝑀𝑀𝑠𝑠𝐶𝐶 𝑇𝑇𝑓𝑓 𝐶𝐶𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇 𝐶𝐶ℎ𝑇𝑇𝑓𝑓𝑇𝑇 = 1.58 𝑚𝑚𝑚𝑚 
ℎ = 9.8 𝑚𝑚𝑚𝑚  
 
 
The design in Figure 9.6 was unsuccessful because of the following: 
• The rigid diaphragm and the uneven inner surfaces of the pump body (obtained 
from FDM (Fused Deposition Modeling) 3D Printing contributed to immense 
friction. 
• The sealing was not sufficient to keep the liquid within the pump body.  
• An attempt at magnetic actuation failed because the magnetic forces were unable 
to overcome the frictional forced.  
The next design was inspired from the keyboards that we use to type theses 
like the one you are reading. Old keyboards had a mechanical scissor switch action 
like the one shown in Figure 9.7 (a) and the scissor design allowed the keys to return 
 
Figure 9.6. Diaphragm Piston pump design 3D printed at the Medical Devices Center. The inner diameter 
(ID) of the pump body is 27.71mm and the outer diameter (OD) is 31.13 mm. These dimensions are 
comparable to a Coca-Cola bottle cap. The overall height is 11.5 mm. The 4 diaphragm ribs around the 
periphery of the pump body as 9.4 mm high. The diameter of the shaft is 2.16 mm. The diaphragm is 27.68 
mm in diameter. The pump body was closed off with a sealed ring (not shown in figure) with a diameter 
of 31.13 mm and thickness of 2.765 mm. The inlet and outlet both had a 10-mm long extrusion from the 
pump body and was 1 mm (0.8 mm) [OD (ID)].  
Pump Body 
Pump Body Diaphragm 
Inlet Outlet 
Diaphragm ribs Central Shaft 
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to their original position after use so that they could be used again. Current 
QWERTY keyboards (especially those used with PCs or Desktops) are usually 
equipped with different audible and tactile switches which create the distinct sounds 
and sensations of typing. A very common one is the rubber dome [Figure 9.7 (b), 
(c)] which has a hard center that is pushed down upon by a plunger below the key 
and this hard center presses against the key matrix which eventually types the word 
one needs. Such keyboards have good tactile responses and are resistant to spills and 
corrosion [57].  
 
              Figure 9.7.  Keyboard switching mechanisms: The Scissor Switch and the Rubber Dome [57]–[59].  
The design inspired from the keyboard’s rubber domes is shown in Figure 
9.8 and the volume calculations can be found alongside the design. Two designs 
using the rubber domes allowed flexibility from a volumetric perspective. Volume 
calculations were necessary for the designs because we were also trying to determine 
the volume of fluid it takes to raise pressure from 20 cmH2O to 120 cmH2O. A 
clinical study to determine this volume in the existing device was conducted and 
will be elaborated upon in a later section.  
 
(a) Scissor switch mechanism 
in old keyboards. 
(b) The layers in a QWERTY 
keyboard incluidng the Rubber 
Dome. 
(c) The Rubber Dome within a 
keyboard
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The design was made with 
the idea that the device can 
be implanted 
subcutaneously and the 
patient simply must activate 
the pump by applying 
pressure on the rubber 
domes. The other advantage 
was that the pump could be filled with volumes up to 1mL, which as it turns out is 
enough to raise the pressure from 20 cmH2O to 120 cmH2O (through the clinical 
study discussed later). The failure of this pump was due to reduced magnetic 
actuation that resulted in ineffective application of force on the fluid within the 
pump.  
Going back to the board and trying out other ideas such as the ones shown 
in Appendix D gave me ideas on the actuation mechanism which must be 
instantaneous, applies uniform compression, and occurs within sufficiently sealed 
conditions. The sealing of pump bodies was the single largest contributing factor for 
the failure of some of these designs. As we proceed further we will discuss other 
major tweaks in the design like completely doing away with the permanent magnets, 
testing different diaphragm materials, and a variety of sealant adhesives.  
 
 
Figure 9.8. The Rubber Dome pump. Sketched on 8/30/2016.  
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9.2.1. Development of the Current Designs 
After the designs shown in Section 9.2 and Appendix D, we tried to design 
pumps that applied uniform pressure on the liquid inside it and the best option was 
designing a system like a syringe. The diaphragm would be rigid and lined by a 
well-lubricated O-ring that traversed the height of the pump body in a frictionless 
manner. The diaphragm, to maintain its alignment at all time was made to pass 
through 3 or 4 shafts. A variation to the design was making the inner lining of 
holes on the diaphragm through which the shafts passed smooth and properly 
sealed such that the O-ring could be done away with. These designs are shown in 
Figure 9.9 (a)-(c). Figure 9.9 (d) uses the idea that a flexible diaphragm can be 
tightened between two pieces designed like a cap-screw and this would naturally 
allow excellent sealing.  
  
 
 
 
(b) 
(a) (c) 
(c) 
(d) 
Figure 9.9. (a) Holes for the pump shafts in a rigid diaphragm (shown in navy blue color); (b) O-Ring 
incorporated design with O-ring seals around the diaphragm (shown in green) and rolling diaphragm seals 
around the shafts within the diaphragm holes (shown in red); (c) Similar pump design without O-rings and 
frictionless surfaces inside the pump for smooth diaphragm movement; (d) A cap-screw design with an 
elastomeric diaphragm sandwiched between the two parts that evenly stretches out over the pump opening 
as the cap is tightened. (The magnets are shown in Black) 
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The designs from a prototyping perspective were hard to implement 
because of the complexity and the interaction of the O-ring seals with the 
diaphragm. If 3-D printed, they would have to be made with a printer that has 
very high resolution for a smooth finish. This could be achieved by injection 
molding but this endeavor would have been very expensive. Additionally, the 
actuation mechanism with magnets had to be tested and that had not been given 
sufficient attention.  We filtered our ideas and brought down the designs to the 4 
shown in Figure 9.10. Each of these designs had a rigid diaphragm and for sealing 
to not cause failure in the design, we decided to put in a miniature life-saver tube 
or the silicone-made AMS 800TM cuff or pressure regulating balloon. These 4 
designs with minor tweaks made on the fly have been the basis of our current 
device.  The designs were built in Onshape (Cambridge, MA, USA)- a cloud 
based CAD software and then 3-D printed for bench testing. The Onshape models 
are shown in Appendix E.   
 
  Figure 9.10. (a) Pump with a life-saver shaped tube for fluid; (b) The usual rigid diaphragm idea as 
shown in Figure 8.9 (c); (c) Pump with AMS 800TM pressure regulating balloon;                                   
(d) A rectangular pump with AMS 800TM cuff. 
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9.3. Designs Incorporated with Electromagnet 
9.3.1. Solenoids: Design and Fabrication 
The idea for the solenoid stems from our initial design depicted in Figure 9.4 and 
9.5. We looked at making our own coils and miniaturize these solenoids for our 
application to make them implantable. Our immediate guess was incorporating 
electromagnetic transducers from hearing aids, despite these coils producing very 
small displacements. Stieger et al., studied the variations of air gap, distance 
between the coil and permanent magnet, diameter of the coil, and uniform pressure 
distribution on a low power milliwatt EM micro speaker using  PDMS membranes 
[60]. Figure 9.11 gives a schematic of the 
arrangement of the coil (CO) and the permanent 
magnet (PM).  
𝑀𝑀0 = 𝑂𝑂𝑠𝑠𝑇𝑇𝑇𝑇𝑇𝑇 𝑀𝑀𝑀𝑀𝑇𝑇𝑚𝑚𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑓𝑓 𝐶𝐶𝑂𝑂 
𝑀𝑀𝑖𝑖 = 𝑈𝑈𝑃𝑃𝑃𝑃𝑇𝑇𝑇𝑇 𝑀𝑀𝑀𝑀𝑇𝑇𝑚𝑚𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑓𝑓 𝐶𝐶𝑂𝑂 
ℎ = 𝐻𝐻𝑇𝑇𝑀𝑀𝑇𝑇ℎ𝑇𝑇 𝑇𝑇𝑓𝑓 𝑁𝑁 − 𝑇𝑇𝑠𝑠𝑇𝑇𝑃𝑃𝐶𝐶 𝑇𝑇𝑓𝑓 𝑇𝑇ℎ𝑇𝑇 𝐶𝐶𝑂𝑂 
𝑀𝑀𝑚𝑚 = 𝐷𝐷𝑀𝑀𝑇𝑇𝑚𝑚𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑓𝑓 𝑃𝑃𝑀𝑀 
ℎ𝑚𝑚 = 𝐻𝐻𝑇𝑇𝑀𝑀𝑇𝑇ℎ𝑇𝑇 𝑇𝑇𝑓𝑓 𝑃𝑃𝑀𝑀 
 
 
 
 
 
 
 
 
Figure 9.11. Schematic drawing of the 
proposed electromagnetic transducer for a 
middle ear hearing aid. A permanent 
magnet (PM) is mounted on the 
manubrium mallei (MM). A coil (CO) is 
placed between the stapes (ST) and the 
round window (RW) on the wall of the 
middle ear cavity (EAC= external 
auditory canal) [60].  
𝑙𝑙2 =  (𝑑𝑑0−𝑑𝑑𝑖𝑖)𝜂𝜂ℎ
2𝑁𝑁
 ; 𝐿𝐿 = 𝑁𝑁𝜋𝜋 𝑑𝑑𝑜𝑜+𝑑𝑑𝑖𝑖
2
 ; 𝑗𝑗 = 𝐼𝐼𝑁𝑁(𝑑𝑑𝑜𝑜−𝑑𝑑𝑖𝑖)ℎ2 
 Cross-section of 
Wire 
Total Length of 
Wire 
Current Density 
Figure 9.12. Results of Force simulations for four different coil 
geometries [51].  
Equation 8.1 [51] 
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The simulation results of different coil configurations (Figure 9.12) showed 
that a minimal diameter, minimal height, and zero-airgap (denoted by the x-axis) 
in a CO gives the maximum force between a PM and a CO. This result will be 
useful in our design when we work on designing our own coils for our application 
and it works completely in our favor since it implies that the device size will be 
smaller. Stieger et al, used a reference coil to compare the results and this coil was 
made up of isolated Cu wire with a diameter of 40µm, length of 1.75m, 166 turns 
and a filling factor (ɳ) or space required between wires of 0.35 [60]. The current 
density produced from the reference coil was 4.46 A/mm2. 
Gradually, we moved from the idea of designing our own solenoid coil to 
acquiring mini-solenoids from the market directly. This was done for time and 
monetary constraints. During this search, we found industrial solenoid valves 
(Figure 9.13) that worked on the principle that a ferromagnetic plunger surrounded 
by a coil will undergo displacement when current passes through the coil [61]. Such 
a valve was called the direct-acting solenoid valve and the law they follow is 
famously known as the Biot-Savart Law. The advantages of using an 
electromagnetic actuator are: 
• Fast response 
• Simple control law- based on flow of current 
• Low manufacturing time and costs 
Several references highlight the importance of the material of the ferromagnetic 
plunger for greater magnetic fields.  
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Using this concept of the solenoid valve, we designed the 
following (Figure 9.14) using the AMS 800TM cuff and 
pressure regulating balloon.  
  
 
We were convinced with the efficacy of the solenoid actuators from Song 
and Lee’s publication on solenoid actuated miniaturized segment robots [62]. The 
ferromagnetic plunger in the solenoids were made of a permanent magnetic core 
and the robots were actuated by alternate in-phase and out-of-phase actuation that 
caused linear and rotatory motions. The design of the solenoid used by Song and 
Lee is shown in Figure 9.15. The solenoid they fabricated has 1250 turns with an 
outer diameter of 15 mm, length of 20 mm and an inner diameter of 5 mm. They 
had a constant input current of 0.6 A, which as we will see in later sections, is very 
high for an implantable device that needs to have a good power saving mechanism. 
Nonetheless, the results from the fabricated solenoid both experimental as well as 
theoretical showed that the pushing force increased with the increase in number of 
turns.  
Figure 9.13. A direct-acting 
solenoid valve with a 
ferromagnetic plunger [61].  Figure 9.14. Pump using a solenoid actuating valve and AMS 800TM components.  
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Solenoid valves operate on a digital principle which means that the coil is 
activated by an electrical current and deactivated without any current. Solenoid 
valves can also be of the latching type which has a permanent magnet built in that 
holds the plunger in a working position without an electrical energy consumption. 
We considered a latching solenoid (Solenoid Push Pulse 5V, Delta Electronics; 
Appendix F) [63] for our prototype but the solenoid drew a very high initial current 
for activation which was beyond the scope of the power supply we had and 
therefore, had to look at other options.   
For our prototype, we used the Mini 5V Push-Pull Solenoid from Adafruit 
Industries LLC (Figure 8.15; Appendix G) [64]. The solenoid has a 3-mm plunger 
stroke and at a rated voltage of 5V and rated current of 1.1A, the solenoid weighs 
12.6g. The solenoid is 12mm by 11mm by 26mm. The technical specifications are 
mentioned in Appendix G.  
 
 
9.3.2. Designs with the Adafruit Solenoid 
When it was time to consider 3D printing, we tried a variety of designs on Onshape 
and this section gives a sneak peek into the designs printed with the Stratasys Fortus 
Figure 9.15. Mini 5V Push-Pull Solenoid from Adafruit Industries LLC (Appendix G) [63] 
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250mc provided to the MIND Lab by the Department of Urology. The design 
variability was dependent on the following: 
• type of diaphragm used 
• the position of the magnet 
• the quality of sealing 
• ease of force application on the diaphragm 
• fluid volume within the pump.  
 
 
 
 
 
 
Inflated AMS 800TM Balloon: 
~20 cc 
20 =  43𝜋𝜋𝑇𝑇3 ⇒ 𝑇𝑇 = 1.7 𝑀𝑀𝑚𝑚 
Assuming balloon is 
rectangular inside the pump 
and the stroke length of the 
Adafruit solenoid is 3 mm, the 
volume of fluid within the 
balloon will be close to 
hemispherical: 
𝑉𝑉𝑇𝑇𝑇𝑇𝑠𝑠𝑚𝑚𝑇𝑇 =  12 × 43𝜋𝜋𝑇𝑇3= 10.34𝑀𝑀𝑀𝑀 
 
Figure 9.16. Mini 5V Push-Pull Solenoid with the pump design 
using the pressure regulating balloon to hold the fluid. (Sketched 
on 5/22/2017) 
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The design in Figure 9.17 was the first design we printed and it failed because of 
incorrect dimensions with respect to the pressure regulating balloon. The other 
mode of failure was that the solenoid did not have a strong base or foundation to sit 
on, and upon actuation, the solenoid wobbled. The same problem was observed    
when we used a surgical nitrile glove 
as a diaphragm instead of a 3D 
printed rigid diaphragm. To create an 
effective seal, we used a Loctite 
Silicone adhesive. The models in 
Figure 9.18 were some attempts 
made at perfecting the design and 
comparing the effectiveness of a 
pump with an in-built fluid chamber 
using the pressure regulating balloon 
versus a pump with a nitrile glove diaphragm. The model with the pressure 
regulating balloon also failed because of a tear in the balloon with constant inflating 
and deflating cycles. The nitrile diaphragm gave a good result but without a strong 
support for the solenoid, the device was wobbly and the force from the solenoid 
actuation did not apply uniform pressure. The sketches for a solenoid support area 
over the pump body are shown in Figure 9.19.  
 
 
Figure 9.17. Oshape design and 3D printe model of
a pump with rigid diaphram to be used with the
pressure regulating balloon.
Top view (from top left to middle bottom-
pump body, rigid diaphragm, solenoid 
plunger base, stopper ring. Isometric View
With a deflated AMS 800TM balloon
Filled Balloon: Dimensions seem to be out 
of place
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An aspect of the pump design that we had not 
considered until now was the volume required to 
raise cuff pressure from 20 cmH2O to 120 
cmH2O and this leads us into the designs that we 
obtained after the IRB approved clinical studies 
that conclusively showed that we need 0.31-0.62 
mL of fluid to reach the desired pressure. The 
Onshape designs and the 3D printed models have 
been shown in Figure 9.20.  
Figure 9.21 shows designs using a lid configuration like the idea presented in Figure 
9.9 (d), where the pump has two components- a pump body with grooves into which 
a lid with a solenoid scaffolding is inserted and while doing so, a nitrile diaphragm 
 
 
     
 
 Figure 9.18. Top Row- 30 mm diameter pump design with in-built solenoid support, pressure regulating balloon. The balloon tore with repeated inflation and deflation during testing. Bottom Row- 34 mm diameter pump with a 
nitrile glove diaphragm and without an in-built solenoid support.   
 
Figure 9.19. Scaffolding for the Mini 5V 
Push-Pull Solenoid with the pump. 
(Sketched on 6/5/2017).  
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is sandwiched between the two parts before it is sealed. This allows better sealing 
and effective translation of actuation force to diaphragm displacement. The design 
also took into consideration volume measurements from the clinical study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.20. Pump designs with in-built solenoid scaffolding and nitrile diaphragms.  
Figure 9.21. The lid design inspired from Figure 8.9 (d)  
  72 
9.4. Characterization of the AMS 800TM Cuff: Pressure vs. Volume  
9.4.1. Pressure vs. Volume: Inside Cuff Only 
Figure 9.22 (b) shows the uneven 
pressure distribution of the cuff with 
the narrow back design. The kinks 
cause uneven pressure profiles around 
the urethra. Mahdi et al., conducted a 
360o pressure profile around the 
urethrato understand the ways in which it varies [65]. Their sensing catheter with a 
series of sensors were used to measure the profiles around the urethra using a 
protractor rotatory system. The GobyTM portable urodynamics system setup is 
shown in Figure 9.23 along with the corresponding data obtained from the sensor 
in relation to the angle as the cuff wraps around the urethra. The results were at 
different values of cuff pressure. 
We used the same setup as Mahdi et 
al., and got the following graphs for pressure 
in cuffs of different sizes. The graphs were 
then fitted along a mathematical curve using 
Microsoft Excel  mathematical1y  
Figure 9.22. (a) AMS 800TM Occlusive Cuffs: 3.5cm, 
4cm, 5 cm, 5.5 cm.  (b) A 4cm cuff at a pressure of 20 
cmH2O.  
 
  
Figure 9.23. (a) GobyTM portable urodynamics system 
setup; (b) Cuff’s cross section after inflation. The blue 
arrows show high pressure locations and the red ones point 
to the angle with low pressure; (c) sensor response to ∆P = 
34 cmH2O at different angles and comparing the average 
value with air-charged balloon sensor; (d) sensor response 
to ∆P = 68cm H2O at different angles; (e) sensor response 
to ∆P = 136cm H2O at different angles. [65] 
(a) (b) 
(a) 
(b) (c) 
(d) (e) 
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gives us the volume required for different cuff sizes to reach 120 cmH2O when used 
outside the body. The equations were solved using Wolfram Alpha. The volume 
ranged between 0.6 – 0.7 mL. 
 
    Graph 9.1. Pressure vs. Volume in Cuff only: Volume required to raise cuff pressure to120 cmH2O in different cuff 
sizes. Polynomial Curve Fitting also shown. Volume determined using Wolfram Alpha.  
9.4.2. Pressure vs. Volume: Around Ovine Urethra 
 
 
        Graph 9.2. Pressure vs. Volume in cuff when around Ovine urethra. Volume determined using Wolfram Alpha. 
  74 
9.4.3. Clinical Study: Pressure-Volume Measurements on the AMS 800TM Cuff 
The University of Minnesota 
Institutional Review Board 
approved this clinical study on 
5/30/2017. We collected pressure 
and volume data while an AUS was 
being implanted. One patient 
underwent a revision surgery and 
was implanted with a tandem cuff of 4 cm and 5 cm sizes, while the other two 
patients were implanted with a 4 cm and 4.5 cm cuff, respectively. The setup as 
shown in Figure 9.24 uses an Edward LifeSciences TruWave pressure transducer 
(Appendix H) which is connected to a pressure measuring system [66]. The 
transducer has a three-way stop cock with an inlet for flushing the system with 
saline, another inlet for providing saline at  intervals of 0.1cc, and an outlet that 
goes to the cuff. The readings from patient 1 do not seem comparable to patient 2 
and 3 and we consider this as errors which would have crept in because it was the 
first time. The procedure was refined for patients 2 and 3.   
 
 
Figure 9.24. Sketch of the setup for the clinical study. 
Figure 9.25. The Edward LifeSciences 
TruWave Pressure Transducer as used in 
the University of Minnesota hospital OR 
setup while operating on Patient 2. The 
TruWave Pressure transducer is 
traditionally used as an anesthesia line 
for arterial pressure, but in this case, will 
be used for a simple pressure-volume 
measurement. [57] 
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Graph 9.3. Pressure vs. Volume in 4 and 5 cm cuff in Patient 1. 
Graph 9.4. Pressure vs. Volume in 4 cm cuff in Patient 2. 
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Graph 9.5. Pressure vs. Volume in a 4.5 cm cuff in Patient 3. 
Graph 9.6. Pressure vs. Volume Comparison in all 3 patients. Volumes at which pressure reaches 120 
cmH2O are mentioned in colored boxes.  
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9.4.4. Conclusions from Ex-Vivo and Clinical Data 
 
 
All equations to determine mathematically the volume needed to raise 
pressure in the cuff to 120 cmH2O were calculated using Wolfram Alpha. When 
used ex-vivo without an ovine urethra, the volume needed was within 0.6-0.7 mL 
(Graph 9.1). When the cuff was placed around the ovine urethra (Figure 9.26), 
volume needed was between 0.15-0.27 mL (Graph 9.2). The reason for such low 
volume is because of the presence of fat around the urethra which applied pressure 
on the cuff as it was being filled with fluid (Figure 9.26). In the ex-vivo and ovine 
urethra studies the size of the cuffs were 4 cm, 5 cm, and 5.5 cm. When the studies 
were done on patients, the urethra is separated from the corpus spongiosum and the 
cuff is wrapped around it after being sized. In patients, the volume required to reach 
Graph 9.7. Pressure vs. Volume in a 4cm cuff- ex-vivo, around ovine urethra and Patients 1 and 2. 
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120 cmH2O was in the range of 0.32-0.75 mL (Graph 9.3-9.6). Since the 4 cm cuff 
was used in majority of the cases so far, a comparison of the said cuff ex vivo, 
around the ovine urethra and the patients gave a volume within the range of 0.17-
0.64 mL (Graph 9.7). As intuition would tell us, the cuff volume when ex-vivo 
would be higher than around the urethra because the urethra applies a back pressure 
on the cuff as it inflates.  
 
 
 
 
 
 
 
Figure 9.26. Pressure vs. Volume measurements around an ovine urethra using the GobyTM portable 
urodynamics system setup 
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10. Other AUSs from the Literature 
During the designing process, an honest survey of publications is essential to 
make the new designs unique and novel. Ruthmann et al. in 2009 published their idea 
for the first ever tele-automatic sphincter prosthesis called the modified German 
Artificial Sphincter System (GASS) or GASS II, which worked at low voltages [67]. 
Their idea was to design a sphincter prosthesis that could work for fecal or urinary 
incontinence as well as in the GI tract. Their design allowed the device to operate 
between -10 V to +20 V and the pump flow rate was 2.23 mL/min [67]. They present 
a high-performance piezoelectric pump that is housed with the fluid reservoir in an 
isolation casing (Figure 10.1).  
 
Figure 10.1. (a) Modified prosthesis GASS II; (b) Design with all mechanical and electrical components; (c) 
filling through the port [67].  
The cuff seen in Figure 10.1(a) is called the Soft-Analband from Agency for 
Medical Innovations (AMI GmbH, Austria) and is much different from the AMS 800TM 
discussed in previous sections. The isolation unit measures 8.3 x 4.5 x 2.7 cm and holds 
the piezo-pump, regulator, microprocessor, telemetry transmitter and receiver coils, 
and rechargeable batteries [67]. From an energy stand-point, the batteries could be used 
for 6 days in the case of urinary incontinence at a rating of 84mAh/ day with inflation 
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and deflation cycles. The battery had a capacity of 570 mAh and 1000 charging cycles. 
This would be a major drawback for an implantable device.  
In 2010, Lamraoui et al., published a design for a novel, automated AUS which 
exerted constant pressure circumferentially around the urethra and the occlusive 
pressure could be controlled with an accuracy of 1 cmH2O. Their motive behind 
coming up with a novel device was the high risk of injuries due to constant urethral 
compression. The device had an electromechanically driven pressure system, wireless 
communication, adaptive pressure regulation mechanism through accelerometer 
sensing, safety system to prevent urinary retention, and control of micturition (Figure 
10.2). The pressure system applied a maximum of 120 cmH2O in a 4cm cuff at a volume 
of 0.5-0.7 mL. The electromechanical pressure system is based on a rolling diaphragm 
attached to an electric motor that generates an occlusive pressure of 500 to 800 cmH2O 
[68]. For this device, the power requirement was 100µW and the entire device had a 
volume of about 60cm3 [68]. The researchers were considering using a transcutaneous  
wireless charging mechanism for effective power 
delivery and reduced hospital visits for 
reimplantations.  
 In 2014, Ramesh et al., came up with a design 
from a materials perspective and introduced the idea of 
using an ionic electro active polymer (EAP) [69]. The 
challenge with any cuff is that it should not restrict 
blood flow through the urethra and the EAP cuff had to take this into consideration. 
Figure 10.2. Lamraoui et al’s 
Automated AUS (AAUS) [68]. 
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EAP bends upon voltage biasing and some of the most common materials used are 
Ionic Polymer Metallic Composite (IPMC), Ionic Polymer Gels (IPG), Carbon 
nanotubes, and conductive polymers. The EAP will circumscribe the urethra and to get 
a material that requires minimum power, researchers had to find one that required 
minimum voltage but produce maximum displacement.  
Hached et al., developed a novel AUS in 2014 which could be operated 
wirelessly and helped control the sphincter rapidly [70]. The implant does away with 
the AMS 800TM control pump so that it can be implanted in women as well. The 
hydraulic circuit is the most important part in any smart AUS, and here Hached et al., 
replace the manual control pump with a micropump and microvalves. They use the 
pressure regulating balloon and study its characteristics during inflation cycles to 
understand its behavior. Considered as a Mooney-Rivlin material, the silicone material 
of the pressure regulating balloon evolves in four distinct phases during inflation. They 
compared their work with Ruthmann’s and Lamraoui’s which is shown in Figure 10.3.  
 
The system shown in Figure 10.4 is 
powered by a 3V battery and uses the 61-70 cmH2O pressure regulating balloon. The 
Li-ion battery used will be able to power the device for 41 days at 3.7V with a power 
rating of 540 mAh that can be recharged 500 times [70]. The components shown in 
Figure 8.4 are encased in cases ranging from 50 x 35 x 20 mm to 50 x 50 x 20 mm. The 
Figure 10.3. Comparision of Ruthmann’s, Lamraoui’s and 
Hached’s work [70]. Figure 10.4. Hached et al.’s wireless AUS and it 
components [70]. 
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smaller case configuration was because of a smaller micropump that was used which 
had a flow-rate of 3 mL/min. Both the prototypes are shown in Figure 10.5.  
Hached et. al published another design in 
2015 and is similar to the black-box 
design shown in Figure 10.5 [71]. The 
new prototype by the authors consists of 
an electromechanical hydraulic system, a 
control unit for hydraulic micro actuators, 
and wireless communication. The hydraulic circuit consists of a centrifugal micropump 
coupled to a latched solenoid between the pressure regulating balloon and the cuff [71].  
Hached et al. compared their device extensively with 
Rathmann’s and Lamraoui’s (Appendix B) and some of 
the positive points of their prototype were that it was 
adaptive to pressure changes, low stand-by power 
consumption, low pumping power and high a pump flow 
rate for a faster response time. Power consumption when 
the pumping occurred was 367 mW [71] . Some of the 
challenges in the prototype were that the implant used 
non-implantable batteries and the device experienced 
heat dissipation and the heat requires a path to escape the 
casing. Overall, all these researchers realize that the UI market is underserved and 
underdeveloped.   
Figure 10.5. Hached’s prototypes with different sizes 
of casing. Size differences were attributed to pump 
sizes used. [71]. 
Figure 10.6. Proposed eAUS prototype 
and pressure control curves. (a) Cuff 
pressure control with proposed voltage 
control method. (A) Pressure curve for 
cuff surrounding 6-mm diameter plastic 
rod simulating presence of the urethra. 
(B) Pressure curve for an empty cuff. (b) 
eAUS prototype compared with classic 
AMS manual pump. (c) Display of eAUS 
internal construction. [71] 
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The most recent development in the eAUS has been the endourethral AUS from 
2016 by Mazzocchi et al [72]. The advantage of an endourethral device is that the 
procedure is minimally invasive and involves the placement of the AUS in the urethral 
lumen. Catheters are the simplest example for endourethral devices, but the idea of 
having an endourethral AUS is not new. Femsoft system by Rochester Medical Corp., 
USA and the InFlow by Vesiflo, Redmond, USA are some of the commercially 
available endourethral systems, used especially in women. These devices are battery 
powered and operated wirelessly by a remote placed close to the device. The wireless 
coupling activates a pump inside the endourethral device that opens a valve allowing 
the bladder to be emptied. A unisex endourethral device is not available and that creates 
a challenge for a device in this category.  
Mazzocchi et al., designed a remote-magnetically controlled endourethral AUS 
(Figure 10.7) and the device disappeared in the body in a quick, less painful procedure, 
allows easy urination, and maintains continence during abdominal contractions or 
physical activity [72].  
 
The device is triggered by an external magnet which is aligned with the device’s 
internal magnet and the magnetic coupling allows the operation of the device. 
(b) (a) Figure 10.7. Concept 
design of the 
endourethral AUS (a) the 
device with its 
components, (b) the main 
components namely the 
safety cursor, spring, valve, 
and the internal magnet. 
[72]. 
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11. Actuation Circuit: Powering the Solenoid  
11.1. Some Basic Concepts 
𝑈𝑈𝑃𝑃𝑀𝑀𝑠𝑠𝑀𝑀𝑇𝑇𝑀𝑀𝐴𝐴𝑀𝑀𝑇𝑇𝑠𝑠 𝑇𝑇𝑓𝑓 𝐶𝐶𝑇𝑇𝑀𝑀𝑇𝑇 (𝐿𝐿) =  𝜇𝜇𝑜𝑜𝜇𝜇𝑟𝑟𝑁𝑁2𝐴𝐴
𝑆𝑆𝐿𝐿
 
 
 
 
 
 
 
𝐺𝐺𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑀𝑀 𝑀𝑀𝑇𝑇𝑀𝑀ℎ𝑇𝑇𝑃𝑃𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇 𝐹𝐹𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇 (𝐹𝐹) ∝ 𝑆𝑆𝑇𝑇𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇ℎ 𝑇𝑇𝑓𝑓 𝑀𝑀𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑀𝑀𝑀𝑀 𝐹𝐹𝑀𝑀𝑇𝑇𝑇𝑇𝑀𝑀 (𝐵𝐵) 
𝐵𝐵 =  𝜇𝜇𝑜𝑜𝜇𝜇𝑟𝑟𝑁𝑁𝑈𝑈 
 
𝐶𝐶𝑠𝑠𝑇𝑇𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇 𝑀𝑀ℎ𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇 𝑀𝑀𝑃𝑃 𝑇𝑇 𝑀𝑀𝑇𝑇𝑀𝑀𝑇𝑇 𝑇𝑇𝑀𝑀𝑀𝑀𝑠𝑠𝑇𝑇𝐶𝐶 𝑇𝑇𝑓𝑓𝑇𝑇𝑇𝑇𝑇𝑇 𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  
𝑀𝑀ℎ𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇 𝑤𝑤𝑀𝑀𝑇𝑇ℎ 𝑇𝑇 90° 𝑝𝑝ℎ𝑇𝑇𝐶𝐶𝑇𝑇 𝐶𝐶ℎ𝑀𝑀𝑓𝑓𝑇𝑇:  
𝑀𝑀𝑈𝑈
𝑀𝑀𝑇𝑇
=  𝑉𝑉
𝐿𝐿   
 
Current can be reduced after activation as a power saving technique and 
reduction in loss of power as heat. An electromagnetic coil behaves as an energy 
storage device and becomes a constant current source when the current is switched 
off. Switching off current abruptly results in voltage increase [73].     
Applying DC voltage to a coil with Inductance L and Internal resistance Ri, the time 
dependent current equation showing discharge of the coil: 
𝑈𝑈(𝑇𝑇) = �1 − 𝑇𝑇−𝑡𝑡 𝜏𝜏� � ×  𝑉𝑉
𝑅𝑅𝑖𝑖
 ;  𝜏𝜏 =  𝐿𝐿
𝑅𝑅𝑖𝑖
  
 
Equivalent circuit of an actuator coil is [73]:    
 
L: Inductivity 
µo: Relative permeability 
µr: Permeability of Core 
A: Coil Surface Area 
N: Number of Windings 
SL: Coil Length 
I: Current flowing through coil 
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Switching characteristics of the coil: 
• Inductance of the coil changes with closing of magnetic circuit. 
• Current change in magnetic circuit is proportional to the applied voltage. 
• The coil is an energy storage, as discussed earlier, and this releases energy 
during switch OFF.  
The switching characteristics give us cues that will help conserve power, 
speed-up actuation, and protect the circuit. A faster activation would require a 
sudden burst of current and brief voltage which can help overcome the static 
mechanical friction from the rest position. The voltage and current can be reduced 
and keep the magnetic circuit closed once the solenoid has been actuated to hold it 
at a certain position. While opening the actuator circuit, the coil tries to maintain a 
constant flow of current and this translated to stored energy which requires a free-
wheeling diode to protect the circuit from over-voltage. A free-wheeling diode does 
this by delaying the switch-off process and extend the time until idle state is reached 
[73]. 
The coil also heats up and the coil resistance will change with change in 
temperature. An EM actuator is mostly made of Copper wire and this produces an 
ohmic internal resistance. The temperature coefficient αCu is 0.00393 per kelvin, 
which implies that a per degree increase in temperature will change the resistance 
by 0.4%. At the same operating voltage, the result is a lower current and longer 
activation time as resistance changes due to temperature. We performed a 
simulation on our foundational circuit to actuate the solenoid and found a variation 
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in actuation characteristics with increase in temperature when the device is ex-vivo 
and in the body at 37oC.  
11.2. Power Reduction Methodologies 
Power reduction in an EM actuator can be done in two ways: 
• Coil Winding Material and Air-Gap in the Coil 
We learnt from Stieger et al., that a minimal diameter, minimal height coil, and 
with zero air-gap will generate the maximum force [60]. Though, this thesis does 
not dive deep into designing a coil from scratch- to increase the efficiency of the 
implantable device, we need to look at designing our own coils. Kartmann et al., 
have a detailed coil design (Figure 11.1) that they designed for a disposable 
dispensing valve for microliter operations [74]. However, our design should 
consider the fact that it should push almost 1mL of fluid in the pump and it 
should do this at a reduced current with a faster actuation time.  
Our device as shown in Figure 
8.9 has three forces- force 
between the plunger and the coil 
(Fplunger), force applied on the 
diaphragm (Fdiaphragm) and 
pressure force of the AMS 800TM 
pressure regulating balloon 
(Fballoon). As common sense would dictate Fdiaphragm + Fballoon < Fplunger. Kartmann 
et al.’s device used a NdFeB magnet as a plunger with an outer dimeter of 2 mm 
Figure 11.1. Kartmann’s coil design (a) CAD model of the 
one-part valve body with an insert molded polyimide 
nozzle. The plunger with a 1 mm thick silicone layer is 
inserted and the valve is closed with a stopper (green); (b) 
Photographs of the first samples of the injection molded, 
disposable, non-contact dispensing valve with and without 
coil. [74]. 
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and length of 10 mm. The maximum force in their device was 50 mN, but our 
device would need greater forces for moving almost a milliliter of fluid. They 
compared the coil designs and although it is not scaled for our device, it gives us 
a good picture about designing a coil that better suits our application (Figure 
11.2).  
 
Using the concepts from section 11.1 and Kartmann et al’s work, we did our own 
calculations for a possible coil that suits out application. The Mini 5V Push-Pull 
Solenoid from Adafruit Industries LLC (Figure 9.15; Appendix G) [64] has a 
rated voltage of 5V and 1.1A. The force rating on it is 80g which is 0.78N. The 
number of turns in the coil were not mentioned on the data sheet and we worked 
our way backwards to calculate N.  
We make some assumptions for our calculations: 
• Diameter of our solenoid are the same as the length of the frame: 12mm 
• The material of the coil is assumed as Copper (µCu: 1.256e-6 H/m) 
• Assume an air-gap (g) between 0.5 to 1 mm  
 
Figure 11.2. Comparison of the dimensions of the prior functional model [5] and the miniaturized design 
of the disposable, electromagnetic dispensing valve [74]. 
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Some other given values were the height of the coil- 20mm, internal resistance 
of 4.5Ω. The inductance (L) of the coil calculated by conducting a simple 
experiment using the concept that in an inductor current lags voltage by 90o, was 
29.1mH (Section 10.3.1).   
                  𝑀𝑀𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇𝑚𝑚𝑇𝑇𝑇𝑇𝑀𝑀𝐴𝐴𝑇𝑇 𝐹𝐹𝑇𝑇𝑇𝑇𝑀𝑀𝑇𝑇 𝐹𝐹𝑚𝑚 = 𝑁𝑁 × 𝑈𝑈 = 𝐻𝐻. 𝐿𝐿;𝐻𝐻:𝑀𝑀𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇𝑀𝑀𝑀𝑀 𝐹𝐹𝑀𝑀𝑇𝑇𝑇𝑇𝑀𝑀 𝑆𝑆𝑇𝑇𝑇𝑇𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇ℎ 
𝑁𝑁 × 1.1𝐴𝐴 = 𝐻𝐻 × 29.1𝑚𝑚𝐻𝐻 ⇒  𝑁𝑁
𝐻𝐻
=   26.45𝑚𝑚𝐻𝐻
𝐴𝐴
 ⇒ 𝐻𝐻 =  𝑁𝑁0.02645𝐻𝐻𝐴𝐴 
𝐹𝐹𝑇𝑇𝑠𝑠𝐹𝐹 𝐷𝐷𝑇𝑇𝑃𝑃𝐶𝐶𝑀𝑀𝑇𝑇𝑠𝑠 𝐵𝐵 =  𝜇𝜇𝐶𝐶𝐶𝐶 × 𝐻𝐻 =  𝜇𝜇𝐶𝐶𝐶𝐶 𝑁𝑁26.45𝑚𝑚𝐻𝐻𝐴𝐴  
𝐶𝐶𝑇𝑇𝑇𝑇𝐶𝐶𝐶𝐶 𝐶𝐶𝑇𝑇𝑀𝑀𝑇𝑇𝑀𝑀𝑇𝑇𝑃𝑃𝑇𝑇𝑇𝑇 𝐴𝐴𝑇𝑇𝑇𝑇𝑇𝑇, 𝑇𝑇 =  𝜋𝜋(62) = 113.04 𝑚𝑚𝑚𝑚2 
𝐹𝐹 = (𝑁𝑁𝑈𝑈)2𝜇𝜇𝑜𝑜𝑇𝑇(2𝑇𝑇2) ⇒ 0.78 𝑁𝑁 =  𝑁𝑁2 ×  1.12 × (4𝜋𝜋 × 10−7) × 0.00011304 𝑚𝑚24 × (𝑇𝑇)2   
⇒ 𝑁𝑁2 = 4540 ⇒ 𝑁𝑁 = 67 𝑇𝑇𝑠𝑠𝑇𝑇𝑃𝑃𝐶𝐶 𝑓𝑓𝑇𝑇𝑇𝑇 𝑇𝑇: 0.5 𝑚𝑚𝑚𝑚 
⇒ 𝑁𝑁2 = 18161 ⇒ 𝑁𝑁 = 135 𝑇𝑇𝑠𝑠𝑇𝑇𝑃𝑃𝐶𝐶 𝑓𝑓𝑇𝑇𝑇𝑇 𝑇𝑇: 1 𝑚𝑚𝑚𝑚 
For any further calculations, we will consider N= 120 turns for the Mini 5V 
Push-Pull Solenoid. 
• Intelligent control through circuitry 
EM actuators ideally should have a zero air-gap for low power requirement. The 
holding current required to hold the solenoid at a position is 40-50% of the 
activation current. Most papers stress on reducing the voltage and current using 
pulse width modulation (PWM) techniques. A simple PWM circuit sets a lower 
average current and has a time-controlled switch-off. The circuit suggested for 
the Mini 5V Push-Pull Solenoid employs this technique at a lower level and is 
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shown in Figure 11.3. The free-wheeling diode is extremely essential to protect 
the coil and the circuit from a sudden current surge.  The current control circuit 
shown in Figure 11.3 is considered a better circuit design.  
Figure 11.4 is a practical 
implementation of the current 
controlled PWM using an IC named 
iC-GE (Appendix J) for coils of 10mH 
to 10H and current ranging from 
100mA to 1A [73].  
 
The resistor Ract helps set the 
activation current which is reduced to 
the holding current using Rhold 
typically after 65ms. The capacitor 
Cact defines the length of the 
activation phase. This design can be 
incorporated in our design for future prototypes. Additionally, Texas 
Instrument’s solenoid driver board with plunger movement [Figure 11.5(c)] 
detection can help determine the amount of pressure we want to apply using our 
pump prototype [75]. Different plunger displacements imply variations of fluid 
pushed out of the pump, which results in different pressure readings. The driver 
Figure 11.3. Comparison of PWM with and without 
current control [73]. 
Figure 11.4. Current control with intelligent coil 
driver iC-GE.  [73]. 
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circuit utilizes the characteristics of the solenoid current [Figure 10.5(a)] in 
detecting movement of the plunger in a solenoid.  
 
 
 
11.3. Mini 5V Push/Pull Solenoid: Further Characterization 
11.3.1. Solenoid Circuit 1 [64] (Appendix K) 
 
 
To power the solenoid, a basic circuit was designed consisting of the solenoid coil 
and a transistor TIP102 which acts as a switch. This circuit was used to test the 
functionality of the solenoid and for all testing purposes. However, in this circuit, 
the solenoid consumes constant rated current throughout the ON period which 
results in a higher power dissipation of the circuit. 
Figure 11.5. Plunger Movement detection circuit: (a) Excitation current characteristic of a 
solenoid; (b) Solenoid energized and the electromagnetic force is strong enough to move the plunger; 
(c) Solenoid driver board having plunger movement detection circuit [75]. 
(a) 
(b) (c) 
Figure 11.6. Solenoid Actuation Circuit 1 as recommended by Adafruit (Appendix K) [64] (Appendix K).  
  91 
11.3.2. Solenoid Circuit 2: Lowering Power Consumption (Appendix K) 
 
 
 
A new and improved circuit is designed to reduce the current consumed during the 
ON period. This circuit consists of an additional parallel RC combination as shown 
in the figure (Figure 10.7). Here, the circuit operation can be differentiated in to 2 
states namely the ON state and HOLD state. During the ON state, the initial pulse 
turns the Q1 on. This initial high frequency spike results in the C1 reducing to a 
short circuit for a brief instant of time i.e., tON. Now, the current follows through 
the path, L1-R1-C1-Q1. Following this tON, the pulse flattens out and the circuit 
now enters the HOLD state where C1 becomes an effective open circuit. Thus, a 
new path for the current is formed i.e., L1-R1-R3-Q1. It is apparent that this forms 
a resistive voltage divider with a hold voltage applied across the solenoid just 
sufficient to preserve the ON state and preventing the plunger from retracting back 
into the chassis. The current consumed by the solenoid in HOLD state is lower than 
Figure 11.7. Solenoid Actuation Circuit 2 for Energy Saving [Appendix K].  
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that of the ON state thereby reducing the effective power consumption of the 
circuit.  
 
11.3.3. Solenoid Force Experiments 
We calculated force generated by the solenoid using the setup shown in Figure 11.8. 
The actuation circuits used were: a simple connection of the solenoid to the power 
supply and the circuit shown in Schematic 1, which was also recommended by 
Adafruit [64].  
In the first setup, the 
solenoid was connected 
directly to the supply 
and this meant at a 
rated voltage of 5V and 
current rating of 1.1A. 
We had to keep in mind that the solenoid would heat up and therefore, had to take 
quick results. There were three observations made which were integral to our idea’s 
fast actuation system and uniform pressure distribution:  
• When the solenoid was connected directly to the supply, it was basically shorted 
and this produced energy loss in the form of heat.  
• The value of force obtained on the scale also varied with time as the coil heated 
up and began to lose its force.  
• The force had a maximum value at impact and then fell and stabilized at a 
certain value. We ensure that we wait for a while before we took the force 
Figure 11.8. Solenoid Force measurements setup 
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readings at stead state. The maximum force at impact was a point in our design’s 
favor since it allowed quick transfer of force from the solenoid plunger to the 
fluid in the pump.  
Table 11.1 shows the force produced at 
different values of voltage and the 
corresponding current. We found that the 
force remains relatively the same when the 
solenoid is connected directly to the supply. 
The region in orange depicts the working 
region of the solenoid such that we could save 
power by operating the solenoid at a lower 
voltage and current rating, thereby requiring less power. Therefore, we want to be 
in the 2.4-3.0V and 0.45-0.58A range. The results obtained from the experiment 
have been listed in Figure 10.9. The HOLD parameters are the minimum voltage 
and current required to hold the solenoid in its position. From the inductance and 
resistance values, we can calculate the time constant and frequency of the coil. 
𝜏𝜏 = 𝐿𝐿
𝑅𝑅
=  29.1𝑚𝑚𝑚𝑚
4.5Ω = 6.46 𝑚𝑚𝐶𝐶; 𝑓𝑓 = 154.87 𝐻𝐻𝐻𝐻 
 
 
 
Table 11.1. Solenoid Force measurements 
using a digital weighing scale when connected 
directly connected to the supply.  
Vrated: 5V 
Irated: 1.1A 
Frated: 80gm 
V(ON)min: 2.6V 
I(ON)min: 0.5A 
V(HOLD)min: 0.95~1.0V 
I(HOLD)min: 80mA~0.1A 
Fexpt: 72~74 gm 
L: 29.1mH 
R: 4.5Ω 
 
 
Figure 11.9. Solenoid 
Characteristics when 
connected to supply 
directly.  
Figure 11.10. Solenoid 
Characteristics when connected to 
Circuit 1 (Section 10.3.1).  
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Figure 11.10 gives the force measurements when connected to circuit 1 and the 
force versus voltage characteristic is shown in Graph 11.1 with a possible 
polynomial curve-fit.  
 
                     Graph 11.1. Force vs. Voltage of the solenoid with Circuit 1. 
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11.3.4. Energy: Possible Implantable Battery Technologies and Wireless 
Communication 
Power calculations for our design are extrapolated from the battery 
technologies used in Medtronic’s Interstim (Sacral Nerve Stimulator for Urinary 
Control) and Medtronic’s Micra Pacing System [76], [77].  
 
 
From Figure 11.9, we calculate the solenoid’s energy requirement and 
battery specifications using Medtronic’s Micra pacing system, first. The coil 
inductor has a time constant of 6.46ms and since it takes some more time to actuate 
the plunger, we consider a total of 10ms to actuate the solenoid. V(ON)min and I(ON)min 
are considered (2.6V, 0.5A) since it’s a lower voltage and current with the same 
amount of force which will be beneficial for power saving. Therefore, PON is 1.3 W 
which means the Energy is 13mJ. V(HOLD)min and I(HOLD)min are 1V and 0.1A, 
respectively which means that the energy required to hold the plunger at its position 
after actuation is 0.409J at a tHOLD OF 4.09s. Total energy (ETot) required by 
solenoid is 0.422J/ cycle for every ON cycle. We assume that each cycle has a 5s 
duration.  
Figure 11.11. Medtronic’s Micra Pacing System and the Sacral Interstim II Neurostimulator [67], 
[68].  
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The Micra pacemaker has a 3V and 120mAh battery which means the Energy (EBa) 
supplied by it is 𝐸𝐸𝐵𝐵𝐵𝐵 = 3 × 120 × 3600 = 1296𝑊𝑊𝐶𝐶 = 1296𝐽𝐽 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑃𝑃𝑠𝑠𝑚𝑚𝑏𝑏𝑇𝑇𝑇𝑇 𝑇𝑇𝑓𝑓 𝐶𝐶𝑠𝑠𝑀𝑀𝑇𝑇𝑇𝑇𝐶𝐶 =  𝐸𝐸𝐵𝐵𝐵𝐵
𝐸𝐸𝑇𝑇𝑜𝑜𝑡𝑡
=  12960.422 = 3071 𝑀𝑀𝑠𝑠𝑀𝑀𝑇𝑇𝑇𝑇𝐶𝐶 
Assuming 20 cycles per day, we have 153.55 days (~ 5 months). Therefore, a 
battery of 3V, 150mAh can power the solenoid for 150 days at 20 cycles/ day. The 
Interstim II on the other hand uses a Lithium silver vanadium oxide hybrid that has 
a capacity of 1.3Ah at 3.2V. Using the same calculations as shown above, we get 
11,090 cycles and on a 20 cycle/ day basis, we get 555 days (~1.5 years). This 
implies that our device would need an inductive wireless charging capability to 
allow patients to charge their device through the skin.  
An additional capability that we tested was the ability of the solenoid to be actuated 
wirelessly using the Particle Photon Wi-Fi [78] enabled microcontroller with a 
robust cloud platform and a powerful STM32 arm Cortex M3 and a Cypress Wi-Fi 
chip as the brain of the 
microcontroller. We powered the 
Photon with a 5V supply and found 
that we could actuate the solenoid 
using our cell phone (Figure 10.12). 
The microcontroller can receive 
firmware updates wirelessly, and this 
will allow us to help adapt our device to a patient’s level of activity in addition to 
other capabilities like plunger movement detection [75].  
Figure 11.12. Wireless Communication with solenoid 
using Photon’s cloud-based interface on a cell-phone. 
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12. Technical Specifications [71]  
 
Table 12.1. Comparative study of features of our prototype and other similar work 
Research 
Group 
Lamraoui et al. 
[59], 2010 
Ruthmann et al. 
[58] (2010) 
Hached et al. 
[62] (2015) This Work 
Pumping 
System 
Rolling 
Diaphragm 
Piezoelectric 
Micropump 
Centrifugal 
Pump 
Solenoid 
Diaphragm 
Pump 
Pumping Power 
Consumption 
Pumping: 500 
mW; Holding: 
0mW 
Pumping: 120 
mW; Holding: 
10mW 
Pumping: 376 
mW; Holding: 
0mW 
Pumping: 
1.3W; 
Holding: 
0.1W 
Occlusive 
System AMS 800 Cuff Custom cuff AMS 800 Cuff 
AMS 800 
Cuff 
Pumping Flow 500-800 cmH2O/s 2.23 mL/min 700 mL/min 
Work to be 
done 
Adaptability 
Features 
With patient 
activity No 
With urethral 
morphology 
With patient 
activity 
Pressure 
Controller PID 
Yes, but not 
indicated 
PID and 
adaptive 
Solenoid 
Plunger 
Detection; 
Wireless 
Firmware 
upgrades 
Batteries Lithium Lithium Lithium and NiMH 
Lithium 
oxide 
Vanadium 
Oxide 
Hybrid 
Communication Enhanced ShockBurst 
MICS (403 
MHz) Bluetooth 4 
Particle 
Photon (Wi-
Fi) 
Wireless Power 
Transfer No 
Inductive Link 
(125 KHz) Qi Protocol 
Work to be 
done 
Based on Figure 8.9. 
Maximum Diameter of Pump Body: 26 mm; Maximum Height: 9.86 mm 
Volume within pump: 2 cc; Height of device (pump + solenoid): 35 mm  
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Current Status and Future Work 
 
 
 
 
The diagrams above depict the working of our add-on device. The add-on device will complement the working of the existing AMS 800 
and will apply a lower pressure on the urethra thereby reducing ischemia and erosion. At times of stress, the pressure will shoot up to 
120 cmH2O into the cuff. The manual control pump gives an additional back-up and maintains the integrity of the device. The add-on 
device will need to be designed to withstand negative pressure when fluid is pulled from the cuff while voiding. This aspect of device 
testing needs further experimentation and analysis and we are working at perfecting the device further from an implantable perspective 
by giving more attention to the power and energy requirements.  
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Appendix A: Findings about AMS 800 Complications from 
Literature Publications (1996-2016) 
 
Reference Nos.  Authors Journal Year 
[79] G. Singh, D.G. Thomas 
British Journal of 
Urology 1996 
 
Number of Patients: 28 with Post-Prostatectomy Incontinence 
Mean Age: 71 years 
Mean Follow-Up: 41 months 
 
  
 
The reoperation rate of 57% was considered very high when compared to prior 
literature with a mean of 27% for reoperation rate.  
Conclusion: 95% continence rate can be achieved with the AUS implantation.  
 
[80] 
S. E. Litwiller, K. 
B. Kim, P. D. 
Fone, R. W. 
deVere White, and 
A. R. Stone 
The Journal of 
Urology 1996 
 
Number of Patients: 65 (50 patients participated in the survey) 
Median Follow-up: 23.4 months 
Mean Age:71 
Preoperative incontinence in the patients was severe. 
90% patients reported continuous leakage; 70% wore on an average 6 pads per day; 
24% wore 7.4 pads daily 
96% would recommend the AUS to a friend with continence issues.  
Despite the successes of the AUS, physicians and patients were worried about 
infection and erosion- adverse post-operative complications.  
 
 
 
 
Figure A.1. (Left) Number of complications and 
reoperations after implanting AUS; (Bottom) 
Outcome after AUS implantation 
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[81] 
F. Haab, B. A. 
Trockman, P. E. 
Zimmern, and G. 
E. Leach 
The Journal of 
Urology 1997 
 
Number of patients: 68 
Mean Follow-up: 7.2 years 
Pad score reduced after AUS implantation: 2.75 PPD to 0.97 PPD 
AUS permanently removed in 4 patients due to urethral erosion.  
Revisions for mechanical failure or urethral atrophy required in 25% of the 
patients.  
Mechanical Failure: 17 of 68 
Urethral Atrophy: 6 of 68 
80% of patients were socially continent at mean follow-up.  
Design modifications made to the AUS in 1987 drastically reduced mechanical 
failure (Figure A.2).  
51-60 cmH2O balloon was used more often compared to higher pressure balloons 
which reduced urethral erosion and atrophy rate.  
 
 
 
[82] D. S. Elliott and D. M. Barrett 
The Journal of 
Urology 1998 
 
Mechanical vs. non-mechanical failure and reoperation rates from 1983-1987 and 
1988- present 
Number of patients: 400 (323 patients met survey criteria) 
Mean Age: 60.4 years 
Mean Follow-up: 68.8 months 
Patients with minimum 18 months of follow-up were included in the study 
AUS implanted at urethra in 272 patients and bladder neck in 52.  
437 operations were required in 323 patients.  
Mechanical failure: fluid leaks, tube kinking, pump malfunction, connector 
separations 
Non-Mechanical failure: cuff erosion, infection, atrophy, pimp malposition 
1983-1987: Non-narrow backing design cuff (139 cuffs places) 
1988- present: narrow backing cuff (184 cuffs placed) 
Non-mechanical failure rate in the non-narrow backing cuff patient portfolio was 
17% and mechanical failure was 21%. On the other hand, in the narrow backing 
Figure A.2. Mechanical failure rate 
significantly reduced after 
improvement of the device in 1987 
[40].  
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cuff patient portfolio, non-mechanical failure rate was 9% and mechanical failure 
rate was 7.6%.  
 
[83] 
S. N. Venn, T. J. 
Greenwell, and A. 
R. Mundy 
The Journal of 
Urology 2000 
 
Review of AUSs inserted more than 10 years ago  
Number of patients: 100 
Median follow-up: 11 years 
84 patients were continent- 27 patients had device replaced due to mechanical 
failure; 21 patients had device removed due to erosion or infection or reimplantation.  
 
Device survival was 66% at 10 years.  
Over the 10 years, 37% devices were removed due to erosion or infection with the 
highest risk in females.  
 
Early revision for mechanical problems involved replacement of the defective 
component or device. Early explantation due to erosion or infection followed by a 
recovery period and implantation was another revision procedure. Device removal 
due to infection or erosion was commonly caused by introduction of infection during 
surgery.  
In some patients, device was removed because of urethral atrophy caused by cuff 
pressure. This is attributed to a high balloon pressure that cannot be controlled. 
Instances where the device is unable to compensate for the increase in intra-
abdominal pressure, patients tend to experience stress incontinence.  
 
[84] 
J. Q. Clemens, T. 
G. Schuster, J. W. 
Konnak, E. J. 
McGUIRE, and G. 
J. Faerber 
The Journal of 
Urology 2001 
 
Revision rate for AUS implanted post-RP 
Number of patients: 70 (showed signs of incontinence post-RP) 
66 patients had postoperative data: 24 required reoperations (36.4% rate), cuff 
revision was 60% 
At 36.4% revision rate, of the 54 procedures- 5 were due to mechanical failure. 
Cuff revision rates in cases of erosion or atrophy were 89% and 60% for 1 and 5 
years, respectively.  
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[85] 
A. E. Gousse, S. 
Madjar, M.-M. 
Lambert, and I. J. 
Fishman 
The Journal of 
Urology 2001 
 
Number of patients: 71 (29 had earlier version of AMS 800TM; 42 had the newer 
narrow-back cuff) 
Mean follow-up: 7.7 years 
Surgical revision required in 29% of the cases due to complications: 25% of which 
were mechanical failure, 4% were erosion, and 1.4% was infection. Device was 
removed from 2 patients due to mechanical failure.  
 
The narrow-back cuff of the AMS 800 has helped reduce the incidence of erosion 
and need for revision.  
 
[86] 
G. V. Raj, A. C. 
Peterson, K. L. 
Toh, and G. D. 
Webster 
The Journal of 
Urology 2005 
 
Comparative study of outcomes after primary and secondary procedures 
Number of patients: 554 
119 patients underwent 159 secondary procedures.  
31 revisions were due to mechanical failure and 88 due to non-mechanical failure.  
Non-mechanical failure included 63 cases of urethral atrophy, 21 cases of erosion.  
Total device replacement was carried out in 75 cases.  
Of the 119 patients who underwent secondary revisions, 91 needed no additional 
surgical intervention, and 28 needed 40 interventions for mechanical and non-
mechanical failures.  
Urethral sub-cuff atrophy was the most common non-mechanical failure and cuff 
leakage was the most common mechanical failure. In sub-cuff atrophy cases, the 
procedure involved downsizing of the cuff and reimplantation. The decision to 
replace the whole device or components of the device lies solely on the physician’s 
discretion based on the condition of the device and health of the urethra. The health 
of the urethra is the most limiting factor in secondary revisions. In such situations, 
physicians chose to place the new cuff distal or proximal to the primary site. 
However, as one moves distal to the primary site, the urethral circumference reduces 
and the spongy surround decreases.   
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5-year durability outcomes for primary and 
secondary AUS implantations were at 80% and 88% 
respectively (Figure A.3). Continence outcomes were 
80% and 82% in primary and secondary procedures, 
respectively.   
 
[87] 
G. V. Raj, A. C. 
Peterson, and G. 
D. Webster 
The Journal of 
Urology 2006 
 
Understanding the eroded AUS from a preoperative perspective 
Number of patients: 637 
54 explantations in 46 patients because of erosions. The institution erosion rate was 
2.2%. Erosions were linked to certain comorbidities like hypertension, coronary 
artery disease, prior radiation therapy and prior AUS revisions. Majority of the 
patients who underwent revisions for erosion had mild incontinence and with 
reimplantations, these patients had a significantly higher rate of second erosions with 
an average of 6.7 months.  
Stemming from [86], here Raj et al. looked 
at  secondary revisions due to erosions and 
involved removal of components of the 
AUS.  
Of the 637 patients, 591 patients 
underwent primary AUS implantation and 
112 underwent secondary revisions.  
 
 
 
Within the 112 patients, 72 patients had sub-cuff urethral atrophy and 40 mechanical 
causes. There has been a significant increase in the number of erosion cases (Figure 
A.4). The paper also looked at durability of the device over time in patients 
undergoing revisions for erosions and other reasons, and found that the durability of 
the device in erosions cases was much lower and patients would be prone to another 
erosion.   The study conclusively showed that the number of patients undergoing 
AUS revisions is increasing.  
 
 
 
 
 
 
 
Figure A.3. Durability of primary and 
secondary AUS implantations [45].  
Figure A.4. Revisions due to Mechanical failure 
vs Non-mechanical failure in the last 12 years 
[46].  
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[88] 
H. H. Lai, E. I. 
Hsu, B. S. Teh, E. 
B. Butler, and T. 
B. Boone 
The Journal of 
Urology 2007 
 
Outcomes from the narrow-backed cuff AUS at Baylor College of Medicine 
Number of patients: 270 (Follow-up data on 218 [Figure A.5] patients were 
available)  
Mean Follow-up: 36.4 months 
Infection rate: 5.5%; Erosion: 6%; Urethral atrophy: 9.6%; mechanical failure: 6%; 
surgical removal/ revision: 27.1% 
Median time for complications: 3.7 months for infection, 19.8 months for erosion, 
29.6 months for atrophy, 68.1 months for failure and 14.4 months for surgery.  
After 5 years, 75% of the patients were free from any revision and 10% did not have 
a functional AUS. The study finds that the risks from infection and erosions 
plateaued by 48 months, unlike risks from atrophy and mechanical failure which 
continued to increase throughout the study. Cuff atrophy was the most common 
complication.  
 
[89] 
S. P. Kim, Z. 
Sarmast, S. 
Daignault, G. J. 
Faerber, E. J. 
McGuire, and J. 
M. Latini 
The Journal of 
Urology 2008 
 
The study highlights AUS complication rates, associated risk factors, quality and 
durability.  
Number of patients: 124 
Mean Follow-up: 6.8 years 
Figure A.5. Patient profiles of 218 patients with 
available follow-up data.  
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Overall complication rate: 37%  
Most common complication: Mechanical failure (29 patients) 
36% experienced complications within 10 years with most events occurring in the 
first 48 months. 10 patients had erosion, 7 had infection.  
12 patients required removal of the device due to infection and erosion.  
 
[90] 
R. C. O’Connor, 
M. B. Lyon, M. L. 
Guralnick, and G. 
T. Bales 
Urology 2008 
 
Effectiveness and complications of single and double cuff AUS 
Number of patients: 56 (single cuff- 28 and double cuff- 28) 
Data available for 47 men (25 single cuff and 22 double cuff) 
Mean Age: 67 years 
Mean Follow-up: 74.1 months for single cuff and 58 months for double cuff 
The double cuff placement is also referred to as tandem-cuff placement. The 
incidence of complications in tandem cuff cases was higher. The double cuff did not 
provide any significant change in continence rates when compared to single cuff. For 
double cuff, social continence rate was 72%.  
 
Of the 22 patients who received tandem cuff placements, 55% reported 
complications that required surgical revisions. Complications in both the single and 
double cuff patient cohort ranged from urethral atrophy, erosion, mechanical failure. 
In tandem cuff cases, the cuff sizes were downsized to reduce atrophy and erosion.  
 
[91] 
F. T. Rocha, C. M. 
Gomes, A. I. 
Mitre, S. Arap, and 
M. Srougi 
Urology 2008 
 
Evaluation of long term efficacy of the AUS 
Number of patients: 40 
Mean age: 68.3 ± 6.3 years 
Mean Follow-up: 27 to 132 months 
Surgical revision rate was 20%  
3 cases of prosthetic infections followed by erosions. 4 patients lost continence 
after two years of implantation because of mechanical failure which required 
device replacement. Continence rate obtained was 90% and there was a significant 
impact on the quality of life of patients when they were no longer incontinent.  
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[92] D. K. Montague Advances in Urology 2012 
 
This paper highlights the fact that majority of the patients who undergo AUS 
implantation have satisfactory results. This review paper lists the following rates for 
complications: 
Infection: 0.465 to 7% 
Cuff erosion: 3.8% to 10% 
Urethral atrophy: 9.6% to 11.4% 
Figure A.6 below summarizes 4 papers that have been discussed earlier and the 
findings have been averaged to give us a better idea on the incidences of 
complications post-implantation. 
 
Figure A.6. Complications rates from 4 references.  
Freedom from mechanical failure was 79% at 5 years and 72% at 10 years 
Most men need 0-1 pad per day and AUSs are susceptible to revision and 
replacement in the future.  
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Appendix B: Comparison of Literature eAUS Prototypes [71] 
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Appendix C: Patent Survey (Courtesy Innography) 
Item Number Inventor(s) Assignee Title 
1 US201720157759 
Wirbisky, Alan G 
Vandeweghe, 
Andrew P 
Boston Scientific 
Scimed, Inc. 
Artificial Sphincter 
system and method 
Abstract: 
The present invention provides an artificial sphincter employing an easily controlled 
electro-mechanical pump system. The artificial sphincter includes an inflatable cuff a 
control pump fluidly coupled to the inflatable cuff and an electro-mechanical pump 
system. The inflatable cuff is adapted to surround a urethra or rectum of the patient to 
facilitate continence. An inflation element or balloon can be included to further control 
pressure to the cuff. 
 
Claims: 
An electro-mechanical artificial sphincter system, comprising: 
 
an adjustable cuff adapted to apply pressure to a bladder neck or a urethra to promote 
continence; 
 
a fluid reservoir portion; and 
 
a centrifugal pump device in fluid communication with the cuff and the fluid reservoir 
portion, with the centrifugal pump capable of forcing fluid to the cuff to inflate the cuff. 
 
an electro-mechanical pump device in operable communication with the fluid chamber 
to displace fluid within the chamber upon actuation to selectively control inflation or 
deflation of the cuff. 
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2 US8801594 B2 Fogarty, Terence M. Fogarty Terence M. 
Fluid control system 
for inflatable 
sphincter prosthese 
Abstract: 
A fluid transfer system for an inflatable sphincter prosthesis is disclosed. The 
implantable inflatable sphincter prosthesis may include a fluid transfer system and at 
least one inflatable cuff for occluding a body channel. The fluid transfer system may 
include an inflate pump a deflate pump and three one-way valves.  
 
Claims: 
An implantable sphincter prosthesis comprising a fluid transfer system and an 
inflatable cuff for occluding a body channel, said fluid transfer system comprising: 
 
an inflate pump having a first elastomeric pump bulb, said first elastomeric pump bulb 
being volitionally deformable to create positive intraluminal pump pressure that forces 
fluid to be exhausted from the inflate pump, wherein, subsequent to volitional 
deformation, said first elastomeric pump bulb is incapable of imposing a negative 
intraluminal inflate pump pressure;  
 
a deflate pump having a second elastomeric pump bulb, said second elastomeric pump 
bulb being volitionally deformable to create a positive intraluminal pump pressure that 
forces fluid to be exhausted from the deflate pump, wherein, subsequent to volitional 
deformation, said second elastomeric pump bulb imposes a negative intraluminal 
deflate pump pressure to cause fluid to fill the deflate pump; 
 
a first one-way valve located between said inflate pump and said inflatable cuff with a 
first fluid flow through said first one-way valve directed from said inflate pump to said 
inflatable cuff; 
 
a second one-way valve located between said deflate pump and said inflate pump with 
a second fluid flow through said second one-way valve directed from said deflate 
pump to said inflate pump, the second one-way valve having a backpressure 
corresponding to a desired intraluminal pressure of the inflatable cuff in an inflated 
state, the first one-way valve having a backpressure greater than the backpressure of 
the second one-way valve; and 
 
a third one-way valve located between said inflatable cuff and said deflate pump with a 
third fluid flow through said third one-way valve directed from said inflatable cuff to 
said deflate pump, the third one-way valve having at least substantially zero 
backpressure, 
 
wherein said fluid transfer system enables fluid to flow from said inflate pump to said 
inflatable cuff when said inflate pump is volitionally deformed to provide patient 
continence, and wherein said third fluid flow enables fluid to flow from said inflatable 
cuff to said deflate pump and said inflate pump upon activation of said deflate pump to 
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permit patient voiding.  
 
3 US6319191B1 Global Medical Devices 
Peter H. Sayet, 
Lloyd A. 
Sutherland, Victor 
Politano 
Implantable body 
fluid flow control 
device 
Abstract 
An apparatus for controlling fluid flow within a host body has a first shell and a second 
shell for coupling with the second shell to form a cylindrical object suitable for engaging 
and surrounding a selected canal with the host body. The cylindrical object is open at 
both ends and has an interior diameter of a dimension making it suitable for fitting over 
the selected host body’s canal such as the urethra. The apparatus also includes a plunger 
for constricting the fluid flow when activated. The plunger may be activated by an 
electrical solenoid or hydraulic or pneumatic activation to move from a free-flow 
position into a constricting position wherein the fluid flow though the canal is 
substantially prevented or reduced. The apparatus can be used for controlling 
incontinence or restricting fluid flow in other body canals. The host-user can activate the 
apparatus with a remote-control device outside the body which communicates with the 
implanted apparatus by means of any wireless communication that transmits a signal to 
the device causing the solenoid to move the plunger into the constricting position. A 
second signal causes the plunger to retract into a free-flow position when the user no 
longer feels the urge to urinate. 
 
Claims 
An implantable incontinence apparatus for selectively controlling urine flow from a 
bladder through an urethra having internal and external walls and diameters, 
respectively, in a host body without having to sever the urethra to implant said 
implantable apparatus in the host body or to operate said implantable device following 
implantation thereof, said implantable apparatus comprising: 
 
a hollow housing, wherein said hollow housing has a plurality of portals for permitting 
fluid from outside of the urethra to flow into said hollow housing to promote tissue 
growth and anchor said implantable incontinence device following implantation 
thereof,  
 
  117 
a stop device within said hollow housing and positioned adjacent a selected portion of 
the external wall of the urethra through which urine flows following implantation of 
said implantable incontinence apparatus into the body host;  
 
an electrically operated constricting piston having a sliding shaft connected to a 
plunger for engaging a certain area of the external wall of the urethra which is opposite 
the selected area of the external wall of the urethra against which said stop device is 
located when said electrically operated constricting piston is activated, said plunger 
having a front on which more than one ridge is formed to create separate pressure 
points against the urethra when the plunger engages the urethra;  
 
a control device for selectively activating said constricting piston;  
 
whereby, when said control device is activated, the plunger when retracted extends to 
an extended position to restrict to restrict the certain area of the exterior wall of the 
urethra against said stop device to reduce the internal diameter of the urethra located 
between the plunger and said stop device to reduce or stop urine flow through the 
urethra, and the plunger when extended retracts to a retracted position to open the 
urethral to permit urine flow there through. 
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Appendix D: Other Designs 
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Appendix E: Onshape Designs for 3-D Printing 
 
 
 
 
 
 
 
 
 
Appendix F: Delta Electronics Push Pull 5V Latching Solenoid 
(DigiKey) [63] 
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Appendix G: Mini 5V Push-Pull Solenoid from Adafruit 
Industries LLC [64] 
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Appendix H: Edward LifeSciences TruWave Pressure 
Transducer [93] 
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Appendix I: TIP 102 (Complementary Silicon Power 
Darlington Transistors)- STMicroelectronics  
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Appendix J: iC-GE PWM Relay/ Solenoid Driver IC (1A) 
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Appendix K: OrCAD Circuit Schematics 
Schematic 1: Adafruit recommended Circuit [64] 
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Schematic 2: Power Reduction Circuit 
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Appendix L: Particle Photon Wi-Fi Module for Wireless 
Communication [78] 
 
